var title_f1_6_1120="Contents: Leukemia myeloproliferative disorders";
var content_f1_6_1120=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/43/3774\">",
"       Oncology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Leukemia myeloproliferative disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Leukemia myeloproliferative disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Acute lymphoblastic leukemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/56/31625\">",
"           Clinical use of minimal residual disease detection in acute lymphoblastic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/25/22938\">",
"           Cytogenetics in acute lymphoblastic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/32/15880\">",
"           Detection of minimal residual disease in acute lymphoblastic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/11/9400\">",
"           General principles of hematopoietic cell transplantation for acute lymphoblastic leukemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/5/23642\">",
"           Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/28/44489\">",
"           Induction therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/44/40649\">",
"           Overview of the outcome of acute lymphoblastic leukemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/58/4009\">",
"           Overview of the presentation and classification of acute lymphoblastic leukemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/6/31850\">",
"           Overview of the treatment of acute lymphoblastic leukemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/15/39161\">",
"           Post-remission therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/26/3497\">",
"           Post-remission therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/55/37753\">",
"           Risk group stratification and prognosis for acute lymphoblastic leukemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/55/33658\">",
"           Therapeutic use and toxicity of high-dose methotrexate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/15/21753\">",
"           Treatment of relapsed or refractory acute lymphoblastic leukemia in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Acute myeloid leukemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/50/39720\">",
"           Classification of acute myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/58/20393\">",
"           Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/42/39594\">",
"           Cytogenetics in acute myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/7/19576\">",
"           Hyperleukocytosis and leukostasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/41/30362\">",
"           Induction therapy for acute myeloid leukemia in younger adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/0/25607\">",
"           Involvement of the central nervous system with acute myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/17/25882\">",
"           Molecular genetics of acute myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/53/14168\">",
"           Overview of the complications of acute myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/33/35354\">",
"           Pathogenesis of acute myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/55/17274\">",
"           Post-remission therapy for acute myeloid leukemia in younger adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/47/43768\">",
"           Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/55/36730\">",
"           Prognosis of acute myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/50/12073\">",
"           Remission criteria in acute myeloid leukemia and monitoring for residual disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/35/39480\">",
"           Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/29/29146\">",
"           Treatment of acute myeloid leukemia in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/51/29498\">",
"           Treatment of relapsed or refractory acute myeloid leukemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Acute promyelocytic leukemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/12/200\">",
"           Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/11/28858\">",
"           Initial treatment of acute promyelocytic leukemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/35/17976\">",
"           Molecular biology of acute promyelocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/37/12888\">",
"           Treatment of relapsed or refractory acute promyelocytic leukemia in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Agnogenic myeloid metaplasia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/63/1018\">",
"           Clinical manifestations and diagnosis of primary myelofibrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/30/25064\">",
"           Pathogenetic mechanisms in primary myelofibrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/3/36922\">",
"           Prognosis and treatment of primary myelofibrosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Chronic lymphoproliferative disorders (including CLL)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/22/20841\">",
"           Clinical features and diagnosis of hairy cell leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/6/24680\">",
"           Epidemiology and clinical manifestations of chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/16/17671\">",
"           Evaluating response to treatment of chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/61/35800\">",
"           Hematopoietic cell transplantation in chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/36/20040\">",
"           Natural killer (NK) cell large granular lymphocyte leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/12/35017\">",
"           Overview of the complications of chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/42/29352\">",
"           Overview of the treatment of chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/38/35431\">",
"           Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/23/42361\">",
"           Pathophysiology and genetic features of chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/13/6362\">",
"           Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/6/15466\">",
"           Staging and prognosis of chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/15/18680\">",
"           Treatment of T cell prolymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/17/4378\">",
"           Treatment of hairy cell leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/46/2793\">",
"           Treatment of large granular lymphocyte leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/46/30442\">",
"           Treatment of relapsed or refractory chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cytogenetics",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/47/18167\">",
"           Chromosomal translocations, deletions, and inversions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/55/28536\">",
"           Cytogenetic and molecular genetic diagnostic tools",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/35/14905\">",
"           Cytogenetics and molecular genetics of myelodysplastic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/42/39594\">",
"           Cytogenetics in acute myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/21/6489\">",
"           General aspects of cytogenetic analysis in hematologic malignancies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/5/41049\">",
"           Genetic abnormalities in hematologic and lymphoid malignancies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/23/42361\">",
"           Pathophysiology and genetic features of chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Essential thrombocythemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/28/18890\">",
"           Diagnosis and clinical manifestations of essential thrombocythemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/28/32202\">",
"           Prognosis and treatment of essential thrombocythemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Myelodysplastic syndromes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/57/41882\">",
"           Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/35/14905\">",
"           Cytogenetics and molecular genetics of myelodysplastic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/39/8826\">",
"           Hematopoietic cell transplantation in myelodysplastic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/54/25450\">",
"           Management of the complications of the myelodysplastic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/26/19880\">",
"           Overview of the treatment of myelodysplastic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/39/34425\">",
"           Prognosis of the myelodysplastic syndromes in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/53/9049\">",
"           Treatment of high or very high risk myelodysplastic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/30/31210\">",
"           Treatment of intermediate, low, or very low risk myelodysplastic syndromes",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Myeloproliferative disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/33/40474\">",
"           Cellular and molecular biology of chronic myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/9/19609\">",
"           Clinical manifestations and diagnosis of chronic myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/63/1018\">",
"           Clinical manifestations and diagnosis of primary myelofibrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/41/27290\">",
"           Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/28/18890\">",
"           Diagnosis and clinical manifestations of essential thrombocythemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/32/9738\">",
"           Diagnostic approach to the patient with suspected polycythemia vera",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/18/33066\">",
"           Hematopoietic cell transplantation in chronic myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/55/7034\">",
"           Initial treatment of chronic myeloid leukemia in chronic phase",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/30/27111\">",
"           Interferon alpha for the treatment of chronic myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/49/31512\">",
"           Molecular genetics of chronic myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/17/29978\">",
"           Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/52/21322\">",
"           Overview of the myeloproliferative neoplasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/16/41225\">",
"           Overview of the treatment of chronic myeloid leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/30/25064\">",
"           Pathogenetic mechanisms in primary myelofibrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/56/28554\">",
"           Prognosis and treatment of polycythemia vera",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/3/36922\">",
"           Prognosis and treatment of primary myelofibrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/20/27976\">",
"           Treatment of chronic myeloid leukemia in accelerated phase",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/40/7816\">",
"           Treatment of chronic myeloid leukemia in blast crisis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/17/20762\">",
"           Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Polycythemia vera",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/32/9738\">",
"           Diagnostic approach to the patient with suspected polycythemia vera",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/17/29978\">",
"           Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/56/28554\">",
"           Prognosis and treatment of polycythemia vera",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-1320DC917E-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f1_6_1120=[""].join("\n");
var outline_f1_6_1120=null;
var title_f1_6_1121="M pneumoniae radiograph";
var content_f1_6_1121=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Plain radiograph: Mycoplasma pneumoniae pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diffuse bilateral interstitial infiltrates with",
"    <em>",
"     M. pneumoniae",
"    </em>",
"    infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dwight A Powell, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_6_1121=[""].join("\n");
var outline_f1_6_1121=null;
var title_f1_6_1122="Patient information: Diverticulitis (The Basics)";
var content_f1_6_1122=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15393\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4834\">",
"          Colonoscopy",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?20/59/21426\">",
"         Patient information: Constipation in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/5/9299\">",
"         Patient information: Diarrhea in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/24/25986\">",
"         Patient information: Stomach ache and stomach upset (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?17/32/17922\">",
"         Patient information: Diverticular disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Diverticulitis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/diverticulitis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H479166650\">",
"      <span class=\"h1\">",
"       What is diverticulitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Diverticulitis is a disorder that can cause belly pain, fever, and problems with bowel movements.",
"     </p>",
"     <p>",
"      The food we eat travels from the stomach through a long tube called the intestine. At the end of that tube is the colon (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      ). That is where bowel movements are stored. The colon sometimes has small pouches in its walls. These pouches are called &ldquo;diverticula.&rdquo; Many people who have these pouches have no symptoms. Diverticulitis happens when these pouches become infected and cause symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H479166657\">",
"      <span class=\"h1\">",
"       What are the symptoms of diverticulitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common symptom of diverticulitis is pain in the left lower part of the belly. Other symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Constipation",
"       </li>",
"       <li>",
"        Diarrhea",
"       </li>",
"       <li>",
"        Nausea and vomiting",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H479166664\">",
"      <span class=\"h1\">",
"       Is there a test for diverticulitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. There are a few tests your doctor or nurse can do to find out if you have diverticulitis. But tests are not always needed. Your doctor or nurse may be able to diagnose you without them. If you do have a test, you might have a:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         CT scan",
"        </strong>",
"        &ndash; A CT scan is a special kind of X-ray.",
"       </li>",
"       <li>",
"        <strong>",
"         Contrast enema",
"        </strong>",
"        &ndash; For this test, the doctor or nurse squirts a special liquid into your anus and then takes an X-ray.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H479166671\">",
"      <span class=\"h1\">",
"       How is diverticulitis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on how bad your symptoms are. If you have mild symptoms, your doctor or nurse will put you on antibiotics and might put you on a clear liquid diet for a short time. That might be all the treatment you need.",
"     </p>",
"     <p>",
"      But if you have severe symptoms, or if you get a fever, you might need to stay in the hospital. There, you can get fluids and antibiotics through a tube in one of your veins. That way you can stop eating and drinking until you get better.",
"     </p>",
"     <p>",
"      If you have a serious infection, the doctor might put a tube into your belly to drain the infection. In very bad cases, people need surgery to remove the part of the colon that is affected.",
"     </p>",
"     <p>",
"      Several months after your infection has been treated, your doctor might recommend that you have a procedure called a colonoscopy (",
"      <a class=\"graphic graphic_figure graphicRef52258 \" href=\"UTD.htm?4/46/4834\">",
"       figure 2",
"      </a>",
"      ). During a colonoscopy, the doctor can look directly inside your colon to count the number of diverticula in your colon and to find out where they are. At the same time, he or she can check signs of cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8835913\">",
"      <span class=\"h1\">",
"       Should I change my diet if I have had diverticulitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have had diverticulitis, it&rsquo;s a good idea to eat a lot of fiber. Good sources of fiber include fruits, oats, beans, peas, and green leafy vegetables. If you do not already eat fiber-rich foods, wait until after your symptoms get better to start.",
"     </p>",
"     <p>",
"      You do NOT need to avoid seeds, nuts, corn, or other similar foods.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H479166678\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/24/25986?source=see_link\">",
"       Patient information: Stomach ache and stomach upset (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9299?source=see_link\">",
"       Patient information: Diarrhea in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/59/21426?source=see_link\">",
"       Patient information: Constipation in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/32/17922?source=see_link\">",
"       Patient information: Diverticular disease (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?1/6/1122?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15393 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-961E418322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_6_1122=[""].join("\n");
var outline_f1_6_1122=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H479166650\">",
"      What is diverticulitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H479166657\">",
"      What are the symptoms of diverticulitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H479166664\">",
"      Is there a test for diverticulitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H479166671\">",
"      How is diverticulitis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8835913\">",
"      Should I change my diet if I have had diverticulitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H479166678\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15393\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4834\">",
"       Colonoscopy",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/59/21426?source=related_link\">",
"      Patient information: Constipation in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9299?source=related_link\">",
"      Patient information: Diarrhea in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/32/17922?source=related_link\">",
"      Patient information: Diverticular disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/24/25986?source=related_link\">",
"      Patient information: Stomach ache and stomach upset (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_6_1123="Calculator: Right to Left Shunt Fraction Qs/Qt";
var content_f1_6_1123=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"Qs_Qt_form\" name=\"Qs_Qt_form\" onkeydown=\"clrResults();\" onkeyup=\"Qs_Qt_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Right to Left Shunt Fraction Qs/Qt",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         pH2O = 47 * e",
"         <sup>",
"          ((Temp-37)/18.4)",
"         </sup>",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         pATM = 760 * e",
"         <sup>",
"          (-Altitude/7000)",
"         </sup>",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         pAO2 = pATM - pH2O - paCO2",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         AaG = pAO2 - paO2",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         Qs/Qt = 100 * ( .0031 * AaG) / ((.0031 * AaG) + 5)",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"      <tr>",
"       <td align=\"right\" width=\"50%\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Input:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Temp",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Temp_param\" onblur=\"Qs_Qt_fx(); minMaxCheck();\" onchange=\"Qs_Qt_fx();\" size=\"6\" type=\"text\" value=\"37\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Temp_unit\" onchange=\"Qs_Qt_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|degC\">",
"              degC",
"             </option>",
"             <option value=\"0.555555555555556|-17.7777777777778|degF\">",
"              degF",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Altitude",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Altitude_param\" onblur=\"Qs_Qt_fx(); minMaxCheck();\" onchange=\"Qs_Qt_fx();\" size=\"6\" type=\"text\" value=\"0\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Altitude_unit\" onchange=\"Qs_Qt_fx();\" style=\"width:105px;\">",
"             <option value=\"0.01|0|cm\">",
"              cm",
"             </option>",
"             <option value=\"0.3048|0|ft\">",
"              ft",
"             </option>",
"             <option value=\"0.0254|0|in\">",
"              in",
"             </option>",
"             <option value=\"1e-06|0|micm\">",
"              micm",
"             </option>",
"             <option value=\"0.001|0|mm\">",
"              mm",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|m\">",
"              m",
"             </option>",
"             <option value=\"1e-09|0|nm\">",
"              nm",
"             </option>",
"             <option value=\"0.9144|0|yd\">",
"              yd",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             paCO2",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"paCO2_param\" onblur=\"Qs_Qt_fx(); minMaxCheck();\" onchange=\"Qs_Qt_fx();\" size=\"6\" type=\"text\" value=\"40\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"paCO2_unit\" onchange=\"Qs_Qt_fx();\" style=\"width:105px;\">",
"             <option value=\"0.00750063755419211|0|Pascal\">",
"              Pascal",
"             </option>",
"             <option value=\"760.002100178515|0|atm\">",
"              atm",
"             </option>",
"             <option value=\"750.063755419211|0|bar\">",
"              bar",
"             </option>",
"             <option value=\"0.735561538478802|0|cmH2O\">",
"              cmH2O",
"             </option>",
"             <option value=\"10|0|cmHg\">",
"              cmHg",
"             </option>",
"             <option value=\"22.4199156928339|0|ftH2O\">",
"              ftH2O",
"             </option>",
"             <option value=\"0.735561538478802|0|gm/sqcm\">",
"              gm/sqcm",
"             </option>",
"             <option value=\"1.86832630773616|0|inH2O\">",
"              inH2O",
"             </option>",
"             <option value=\"25.4000840071406|0|inHg\">",
"              inHg",
"             </option>",
"             <option value=\"7.50063755419211|0|kPa\">",
"              kPa",
"             </option>",
"             <option value=\"0.750063755419211|0|mbar\">",
"              mbar",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|mmHg\">",
"              mmHg",
"             </option>",
"             <option value=\"51.7150957831416|0|psi\">",
"              psi",
"             </option>",
"             <option value=\"1|0|torr\">",
"              torr",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             paO2",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"paO2_param\" onblur=\"Qs_Qt_fx(); minMaxCheck();\" onchange=\"Qs_Qt_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"paO2_unit\" onchange=\"Qs_Qt_fx();\" style=\"width:105px;\">",
"             <option value=\"0.00750063755419211|0|Pascal\">",
"              Pascal",
"             </option>",
"             <option value=\"760.002100178515|0|atm\">",
"              atm",
"             </option>",
"             <option value=\"750.063755419211|0|bar\">",
"              bar",
"             </option>",
"             <option value=\"0.735561538478802|0|cmH2O\">",
"              cmH2O",
"             </option>",
"             <option value=\"10|0|cmHg\">",
"              cmHg",
"             </option>",
"             <option value=\"22.4199156928339|0|ftH2O\">",
"              ftH2O",
"             </option>",
"             <option value=\"0.735561538478802|0|gm/sqcm\">",
"              gm/sqcm",
"             </option>",
"             <option value=\"1.86832630773616|0|inH2O\">",
"              inH2O",
"             </option>",
"             <option value=\"25.4000840071406|0|inHg\">",
"              inHg",
"             </option>",
"             <option value=\"7.50063755419211|0|kPa\">",
"              kPa",
"             </option>",
"             <option value=\"0.750063755419211|0|mbar\">",
"              mbar",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|mmHg\">",
"              mmHg",
"             </option>",
"             <option value=\"51.7150957831416|0|psi\">",
"              psi",
"             </option>",
"             <option value=\"1|0|torr\">",
"              torr",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Results:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             pH2O",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"pH2O_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <select class=\"medCalcFontSelect\" name=\"pH2O_unit\" onchange=\"Qs_Qt_fx();\" style=\"width:105px;\">",
"              <option value=\"0.00750063755419211|0|Pascal\">",
"               Pascal",
"              </option>",
"              <option value=\"760.002100178515|0|atm\">",
"               atm",
"              </option>",
"              <option value=\"750.063755419211|0|bar\">",
"               bar",
"              </option>",
"              <option value=\"0.735561538478802|0|cmH2O\">",
"               cmH2O",
"              </option>",
"              <option value=\"10|0|cmHg\">",
"               cmHg",
"              </option>",
"              <option value=\"22.4199156928339|0|ftH2O\">",
"               ftH2O",
"              </option>",
"              <option value=\"0.735561538478802|0|gm/sqcm\">",
"               gm/sqcm",
"              </option>",
"              <option value=\"1.86832630773616|0|inH2O\">",
"               inH2O",
"              </option>",
"              <option value=\"25.4000840071406|0|inHg\">",
"               inHg",
"              </option>",
"              <option value=\"7.50063755419211|0|kPa\">",
"               kPa",
"              </option>",
"              <option value=\"0.750063755419211|0|mbar\">",
"               mbar",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mmHg\">",
"               mmHg",
"              </option>",
"              <option value=\"51.7150957831416|0|psi\">",
"               psi",
"              </option>",
"              <option value=\"1|0|torr\">",
"               torr",
"              </option>",
"             </select>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             pATM",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"pATM_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <select class=\"medCalcFontSelect\" name=\"pATM_unit\" onchange=\"Qs_Qt_fx();\" style=\"width:105px;\">",
"              <option value=\"0.00750063755419211|0|Pascal\">",
"               Pascal",
"              </option>",
"              <option value=\"760.002100178515|0|atm\">",
"               atm",
"              </option>",
"              <option value=\"750.063755419211|0|bar\">",
"               bar",
"              </option>",
"              <option value=\"0.735561538478802|0|cmH2O\">",
"               cmH2O",
"              </option>",
"              <option value=\"10|0|cmHg\">",
"               cmHg",
"              </option>",
"              <option value=\"22.4199156928339|0|ftH2O\">",
"               ftH2O",
"              </option>",
"              <option value=\"0.735561538478802|0|gm/sqcm\">",
"               gm/sqcm",
"              </option>",
"              <option value=\"1.86832630773616|0|inH2O\">",
"               inH2O",
"              </option>",
"              <option value=\"25.4000840071406|0|inHg\">",
"               inHg",
"              </option>",
"              <option value=\"7.50063755419211|0|kPa\">",
"               kPa",
"              </option>",
"              <option value=\"0.750063755419211|0|mbar\">",
"               mbar",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mmHg\">",
"               mmHg",
"              </option>",
"              <option value=\"51.7150957831416|0|psi\">",
"               psi",
"              </option>",
"              <option value=\"1|0|torr\">",
"               torr",
"              </option>",
"             </select>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             pAO2",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"pAO2_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <select class=\"medCalcFontSelect\" name=\"pAO2_unit\" onchange=\"Qs_Qt_fx();\" style=\"width:105px;\">",
"              <option value=\"0.00750063755419211|0|Pascal\">",
"               Pascal",
"              </option>",
"              <option value=\"760.002100178515|0|atm\">",
"               atm",
"              </option>",
"              <option value=\"750.063755419211|0|bar\">",
"               bar",
"              </option>",
"              <option value=\"0.735561538478802|0|cmH2O\">",
"               cmH2O",
"              </option>",
"              <option value=\"10|0|cmHg\">",
"               cmHg",
"              </option>",
"              <option value=\"22.4199156928339|0|ftH2O\">",
"               ftH2O",
"              </option>",
"              <option value=\"0.735561538478802|0|gm/sqcm\">",
"               gm/sqcm",
"              </option>",
"              <option value=\"1.86832630773616|0|inH2O\">",
"               inH2O",
"              </option>",
"              <option value=\"25.4000840071406|0|inHg\">",
"               inHg",
"              </option>",
"              <option value=\"7.50063755419211|0|kPa\">",
"               kPa",
"              </option>",
"              <option value=\"0.750063755419211|0|mbar\">",
"               mbar",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mmHg\">",
"               mmHg",
"              </option>",
"              <option value=\"51.7150957831416|0|psi\">",
"               psi",
"              </option>",
"              <option value=\"1|0|torr\">",
"               torr",
"              </option>",
"             </select>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             AaG",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"AaG_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <select class=\"medCalcFontSelect\" name=\"AaG_unit\" onchange=\"Qs_Qt_fx();\" style=\"width:105px;\">",
"              <option value=\"0.00750063755419211|0|Pascal\">",
"               Pascal",
"              </option>",
"              <option value=\"760.002100178515|0|atm\">",
"               atm",
"              </option>",
"              <option value=\"750.063755419211|0|bar\">",
"               bar",
"              </option>",
"              <option value=\"0.735561538478802|0|cmH2O\">",
"               cmH2O",
"              </option>",
"              <option value=\"10|0|cmHg\">",
"               cmHg",
"              </option>",
"              <option value=\"22.4199156928339|0|ftH2O\">",
"               ftH2O",
"              </option>",
"              <option value=\"0.735561538478802|0|gm/sqcm\">",
"               gm/sqcm",
"              </option>",
"              <option value=\"1.86832630773616|0|inH2O\">",
"               inH2O",
"              </option>",
"              <option value=\"25.4000840071406|0|inHg\">",
"               inHg",
"              </option>",
"              <option value=\"7.50063755419211|0|kPa\">",
"               kPa",
"              </option>",
"              <option value=\"0.750063755419211|0|mbar\">",
"               mbar",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mmHg\">",
"               mmHg",
"              </option>",
"              <option value=\"51.7150957831416|0|psi\">",
"               psi",
"              </option>",
"              <option value=\"1|0|torr\">",
"               torr",
"              </option>",
"             </select>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Qs/Qt",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"QsQt_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <select class=\"medCalcFontSelect\" name=\"QsQt_unit\" onchange=\"Qs_Qt_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|%\">",
"               %",
"              </option>",
"              <option value=\"100|0|fraction\">",
"               fraction",
"              </option>",
"              <option value=\"100|0|ratio\">",
"               ratio",
"              </option>",
"             </select>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"3\">",
"            &nbsp;",
"            <br/>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"center\" colspan=\"3\">",
"            <span class=\"medCalcFontOneBold\">",
"             Decimal Precision:",
"            </span>",
"            <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"Qs_Qt_fx();\">",
"             <option>",
"              0",
"             </option>",
"             <option>",
"              1",
"             </option>",
"             <option selected=\"selected\">",
"              2",
"             </option>",
"             <option>",
"              3",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontOneBold\">",
"     Notes",
"    </span>",
"    <ul class=\"medCalcFontOne\">",
"     <li>",
"      This calculation should only be applied to a situation in which the subject has been breathing 100% O2 for at least 20 minutes.",
"     </li>",
"     <li>",
"      For this test to be valid the subject should have a normal baseline Aa Gradient and normal O2 consumption.",
"     </li>",
"     <li>",
"      The equations above simplify the traditional Aa Gradient calculation because FIO2 and the respiratory quotient are both assumed to be 1 after nitrogen washout.",
"     </li>",
"     <li>",
"      Top normal shunt is approximately 5%.",
"     </li>",
"    </ul>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontRef\">",
"     <b>",
"      References",
"     </b>",
"    </span>",
"    <ol>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       Chiang ST. A nomogram for venous shunt (Qs-Qt) calculation.",
"       <i>",
"        Thorax",
"       </i>",
"       . 1968 Sep;23(5):563-5.",
"      </span>",
"     </li>",
"    </ol>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_6_1123=[" /* <![CDATA[ */",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function Qs_Qt_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.Qs_Qt_form){",
"",
"",
"doCalc = true;",
"if (Temp_param.value.indexOf(',') >= 0){ Temp_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Temp_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Temp_unit.options[Temp_unit.selectedIndex].value.split('|');",
"Temp = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Altitude_param.value.indexOf(',') >= 0){ Altitude_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Altitude_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Altitude_unit.options[Altitude_unit.selectedIndex].value.split('|');",
"Altitude = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (paCO2_param.value.indexOf(',') >= 0){ paCO2_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(paCO2_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = paCO2_unit.options[paCO2_unit.selectedIndex].value.split('|');",
"paCO2 = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (paO2_param.value.indexOf(',') >= 0){ paO2_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(paO2_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = paO2_unit.options[paO2_unit.selectedIndex].value.split('|');",
"paO2 = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"pH2O =  47 * eTo((Temp - 37) / 18.4);",
"",
"unit_parts = pH2O_unit.options[pH2O_unit.selectedIndex].value.split('|');",
"if (doCalc) pH2O_param.value = fixDP((pH2O - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"pATM =  760 * eTo(- Altitude / 7000);",
"",
"unit_parts = pATM_unit.options[pATM_unit.selectedIndex].value.split('|');",
"if (doCalc) pATM_param.value = fixDP((pATM - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"pAO2 =  pATM - pH2O - paCO2;",
"",
"unit_parts = pAO2_unit.options[pAO2_unit.selectedIndex].value.split('|');",
"if (doCalc) pAO2_param.value = fixDP((pAO2 - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"AaG =  pAO2 - paO2;",
"",
"unit_parts = AaG_unit.options[AaG_unit.selectedIndex].value.split('|');",
"if (doCalc) AaG_param.value = fixDP((AaG - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"QsQt =  100 * ( .0031 * AaG) / ((.0031 * AaG) + 5);",
"",
"unit_parts = QsQt_unit.options[QsQt_unit.selectedIndex].value.split('|');",
"if (doCalc) QsQt_param.value = fixDP((QsQt - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.Qs_Qt_form){",
"",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.Qs_Qt_form){",
"",
"pH2O_param.value = '';",
"pATM_param.value = '';",
"pAO2_param.value = '';",
"AaG_param.value = '';",
"QsQt_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"/* ]]> */"].join("\n");
var outline_f1_6_1123=null;
var title_f1_6_1124="Sodium citrate: Patient drug information";
var content_f1_6_1124=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sodium citrate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/13/14547?source=see_link\">",
"     see \"Sodium citrate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/21/26963?source=see_link\">",
"     see \"Sodium citrate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cytra-2;",
"     </li>",
"     <li>",
"      Oracit&reg;;",
"     </li>",
"     <li>",
"      Shohl's Solution (Modified)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F221728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PMS-Dicitrate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691886",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high acid levels in the blood.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower acid levels in the urine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702936",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sodium citrate, citric acid, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703827",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have very bad kidney disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are on a low-salt or salt-free diet.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High potassium level. Signs include feeling weak, lightheaded, dizzy, feel like passing out, or have numbness or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699070",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695821",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 15 to 30 minutes after meals and at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695451",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix with",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        2",
"       </sub>",
"       glass of water and drink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694620",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chill to make it taste better.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11426 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-A58E39C754-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_6_1124=[""].join("\n");
var outline_f1_6_1124=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221727\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221728\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013240\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013239\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013244\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013245\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013247\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013242\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013243\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013248\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013249\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/13/14547?source=related_link\">",
"      Sodium citrate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/21/26963?source=related_link\">",
"      Sodium citrate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_6_1125="Hydrocephalus due to germinal matrix intraventricular hemorrhage";
var content_f1_6_1125=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71951%7EPEDS%2F82502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71951%7EPEDS%2F82502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Hydrocephalus due to germinal matrix intraventricular hemorrhage (IVH) of prematurity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound in an infant with grade IV intraventricular hemorrhage.",
"    <br>",
"     (Panel A) Coronal view.",
"     <br>",
"      (Panel B) Sagittal view.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Courtesy of Drs. Abilash Haridas and Tadanori Tomita.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Post hemorrhagic hydrocephalus sequelae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 297px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal T2 weighted MRI in a child with communicating hydrocephalus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drs. Abilash Haridas and Tadanori Tomita.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_6_1125=[""].join("\n");
var outline_f1_6_1125=null;
var title_f1_6_1126="Fluorescein AMD";
var content_f1_6_1126=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Fluorescein angiography and color fundus photography of the right eye in a patient with a classic choroidal neovascular membrane",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 428px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) The first image of the fluorescein angiogram was taken 25 seconds after intravenous administration of 5 cc of 10 percent fluorescein dye. There is a well-defined focal area of hyperfluorescence seen in the macula. B) The second image was taken at 1 minute and 2 seconds after dye administration. It demonstrates fluorescein dye in both the retinal arteries and veins. The focal area of hyperfluorescence has increased in intensity. C) The third image was taken 14 minutes and 27 seconds after dye administration. Little fluorescence is seen in the retinal arteries and veins. The focal area of hyperfluorescence has developed fuzzy borders due to leakage of fluorescein dye into the subretinal space, consistent with abnormal new vessals. D) The fourth image demonstrates color fundus photography. A whitish lesion in the macula located inferonasal to the fovea corresponds to the hyperfluorescent area in the dye study.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_6_1126=[""].join("\n");
var outline_f1_6_1126=null;
var title_f1_6_1127="Evaluation of gross hematuria in children";
var content_f1_6_1127=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of gross hematuria in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/6/1127/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/6/1127/contributors\">",
"     Marie France Gagnadoux, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/6/1127/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/6/1127/contributors\">",
"     Patrick Niaudet, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/6/1127/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/6/1127/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/6/1127/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/6/1127/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gross hematuria is defined by the presence of an increased number of red blood cells (RBCs) in the urine that is visible to the naked eye. Although an uncommon occurrence in children, nevertheless it is a disturbing finding for both the affected child and",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    family.",
"   </p>",
"   <p>",
"    The causes and evaluation of gross hematuria in children will be reviewed here. The evaluation of children with microscopic hematuria is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30584?source=see_link\">",
"     \"Evaluation of microscopic hematuria in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DETECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gross hematuria is suspected when red or brown urine is present. However, red or brown urine can be due to causes other than blood including the following (",
"    <a class=\"graphic graphic_table graphicRef56337 \" href=\"UTD.htm?24/52/25419\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pigments from drugs (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/23/7539?source=see_link\">",
"       phenazopyridine",
"      </a>",
"      ) or foods (eg, beets)",
"     </li>",
"     <li>",
"      Metabolites associated with other clinical conditions (eg, porphyria)",
"     </li>",
"     <li>",
"      Free hemoglobin or myoglobin",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the initial step in the evaluation of patients with red urine is to establish whether or not the urine discoloration is due to blood or another substance. This is accomplished by the following two procedures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinary dipstick test for blood &mdash; The reagent strip that detects blood utilizes",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"       hydrogen peroxide",
"      </a>",
"      , which catalyzes a chemical reaction between hemoglobin (or myoglobin) and the chromogen tetramethylbenzidine. If the urinary dipstick test is positive for blood, the likely cause of the",
"      <span class=\"nowrap\">",
"       red/brown",
"      </span>",
"      pigmentation is blood, or free hemoglobin or myoglobin. A negative test eliminates these etiologies as the cause of urinary discoloration.",
"     </li>",
"     <li>",
"      Urine centrifugation &mdash; If after centrifugation of the urine specimen, the sediment is",
"      <span class=\"nowrap\">",
"       red/brown",
"      </span>",
"      then the etiology is most likely blood (",
"      <a class=\"graphic graphic_algorithm graphicRef55923 \" href=\"UTD.htm?22/63/23550\">",
"       algorithm 1",
"      </a>",
"      ). If the supernatant is",
"      <span class=\"nowrap\">",
"       red/brown",
"      </span>",
"      and the sediment is not discolored, than the",
"      <span class=\"nowrap\">",
"       red/brown",
"      </span>",
"      urine is not due to blood but to another substance, such as free hemoglobin or myoglobin. Microscopic examination of the sediment should confirm the presence of red blood cells. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link&amp;anchor=H4#H4\">",
"       \"Urinalysis in the diagnosis of kidney disease\", section on 'Red to brown urine'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with gross hematuria, the color change does not necessarily reflect the degree of blood loss, since as little as 1 mL of blood per liter of urine can induce a visible color change.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly identified etiologies for gross hematuria in children include urinary tract infection (UTI), irritation of the meatus or perineum, and trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1127/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Other less common causes include nephrolithiasis, sickle cell",
"    <span class=\"nowrap\">",
"     disease/trait,",
"    </span>",
"    coagulopathy, glomerular disease including postinfectious glomerulonephritis and IgA nephropathy, malignancies (eg, Wilms' tumor and rarely transitional cell carcinoma of the bladder), and drug-induced hemorrhagic cystitis, such as seen with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1127/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative frequency of the known causes of gross hematuria in children varies depending upon the clinical setting. This is illustrated by several case series of children with gross hematuria who presented to three different clinical settings (ie, a pediatric emergency room [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1127/abstract/1\">",
"     1",
"    </a>",
"    ], a pediatric urology referral service [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1127/abstract/3\">",
"     3",
"    </a>",
"    ], or a pediatric nephrology referral service [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1127/abstract/4\">",
"     4",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    In a 1977 two-year retrospective review of 150 patients presenting to a tertiary pediatric emergency center with gross hematuria, either documented (n=39) or suspected (n=35) urinary tract infection (UTI) was the underlying diagnosis in half of the patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1127/abstract/1\">",
"     1",
"    </a>",
"    ]. Other causes included perineal or urethral irritation (18 percent), trauma (7 percent), acute nephritis (4 percent), coagulopathy (3 percent), and stone (2 percent). In 10 percent of patients, no etiology was found.",
"   </p>",
"   <p>",
"    In a 10-year retrospective review of 342 children who presented with gross hematuria to a pediatric urologic center in the United States between 1994 and 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1127/abstract/3\">",
"     3",
"    </a>",
"    ], the causes of gross hematuria and their frequency included urethral irritation or trauma (15 percent), urinary tract infection (14 percent), underlying congenital anomalies, such as vesicoureteral reflux (VUR), posterior urethral valves, or ureteropelvic junction obstruction, (13 percent), nephrolithiasis (5 percent), and malignancy (1 percent). In 35 percent of the patients, no cause could be determined. In addition, bladder or urethral abnormalities were seen in 76 of 136 patients who underwent cystoscopy including posterior urethritis (n=25), cystitis (n=25), bladder trabeculation (n=7), and urethral stricture (n=6).",
"   </p>",
"   <p>",
"    In this urologic case series, there were no cases of glomeruli disease, which is most likely due to referral bias. This was illustrated by the third retrospective case series from a pediatric nephrology referral center that demonstrated a greater proportion of cases due to glomerular disease compared to both of the two previous studies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1127/abstract/4\">",
"     4",
"    </a>",
"    ]. In this review, results were based upon 82 of 100 patients with completed evaluation. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A glomerular cause was identified in 24 patients (29 percent). The two most common diagnoses were IgA nephropathy (n=13) and Alport syndrome (n=6). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1337?source=see_link\">",
"       \"Clinical presentation and diagnosis of IgA nephropathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=see_link\">",
"       \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonglomerular etiology was established in 30 patients (37 percent). The most common diagnoses were hypercalciuria (n=9), urethral irritation or trauma (n=8), and hemorrhagic cystitis (n=7).",
"     </li>",
"     <li>",
"      No cause was found in the remaining 28 patients (34 percent). In 26 of these patients, the hematuria was attributed to a nonglomerular source.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the two referral based studies, boys were at a higher risk for gross hematuria than girls because of their increased susceptibility to trauma of the urethral meatus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1127/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. However, in the first study, there was no gender difference. The increased prevalence of female patients with gross hematuria due to urinary tract infections seen in the emergency room setting appears to have offset the predominance of boys with recurrent gross hematuria due to trauma resulting in the reported equal distribution of boys and girls [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1127/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of children who present with gross hematuria have an easily recognizable and apparent cause [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1127/abstract/1\">",
"     1",
"    </a>",
"    ]. The clinician generally is able to establish the underlying etiology by a complete history, physical examination, and urinalysis (",
"    <a class=\"graphic graphic_algorithm graphicRef68294 \" href=\"UTD.htm?3/59/4017\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Historical clues",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are often clues from the history that point toward a specific diagnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recent vigorous exercise or trauma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27973?source=see_link\">",
"       \"Exercise-induced hematuria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      History of new onset of incontinence, dysuria, frequency, or urgency, suggests UTI as a possible cause. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical features and diagnosis of urinary tract infections in infants and children older than one month\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      History of unilateral flank pain that may radiate to the groin suggests obstruction caused by a calculus or blood clot. In comparison, flank pain without radiation but with fever, dysuria, and frequency",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      urgency is suggestive of acute pyelonephritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical features and diagnosis of urinary tract infections in infants and children older than one month\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The timing of hematuria during micturition, especially terminal hematuria, suggests urethral bleeding.",
"     </li>",
"     <li>",
"      The color of urine may distinguish glomerular bleeding from extraglomerular bleeding. Glomerulonephritis is associated with brown urine. Bleeding from the lower urinary tract is suggested by pink or red urine and may be accompanied by blood clots. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link&amp;anchor=H10#H10\">",
"       \"Etiology and evaluation of hematuria in adults\", section on 'Glomerular versus nonglomerular bleeding'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H7\">",
"       'Urinalysis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      A history of pharyngitis or impetigo (two or three weeks prior to onset of hematuria) suggests poststreptococcal glomerulonephritis, although a recent upper respiratory (one or two days prior to onset of hematuria) infection can be associated with IgA nephropathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link&amp;anchor=H14578038#H14578038\">",
"       \"Differential diagnosis and evaluation of glomerular disease\", section on 'Hematuria following upper respiratory infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A history of predisposing clinical conditions such as sickle cell disease or trait [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1127/abstract/5\">",
"       5",
"      </a>",
"      ] or coagulopathy such as severe hemophilia.",
"     </li>",
"     <li>",
"      Exposure to medications that can cause hemorrhagic cystitis (such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ), or nephritis (although hematuria is not typically the central manifestation in such patients). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical manifestations and diagnosis of acute interstitial nephritis\", section on 'Drugs'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should include measurement of blood pressure, assessment for edema and recent weight gain, close skin examination (eg, purpura), direct visualization of the genitals (looking for penile urethral meatal erosion or female introitus pathology), and evaluation for abdominal discomfort or masses (eg, Wilms' tumor).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Urinalysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the urine may suggest an underlying etiology and potential site of bleeding (glomerular versus extraglomerular).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glomerular bleeding &mdash; Signs of glomerular bleeding include red cell casts (pathognomonic for glomerular disease) (",
"      <a class=\"graphic graphic_picture graphicRef55778 \" href=\"UTD.htm?34/38/35424\">",
"       picture 1",
"      </a>",
"      ); red cells having a dysmorphic appearance; and brown, cola-colored urine (",
"      <a class=\"graphic graphic_table graphicRef65786 \" href=\"UTD.htm?6/26/6571\">",
"       table 2",
"      </a>",
"      ). In a first morning urinary sample, protein excretion greater than 100",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      at a time when there is no gross bleeding is also indicative of glomerular source of blood. Although helpful if present, the absence of these findings does not exclude glomerular disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Morphologic study of urinary RBCs, particularly with a phase-contrast microscope, may be helpful in distinguishing glomerular from nonglomerular bleeding. The presence of more than 30 percent dysmorphic RBCs or of more than 5 percent of a specific form named an \"acanthocyte\" is highly suggestive of glomerular hematuria (",
"    <a class=\"graphic graphic_picture graphicRef79440 graphicRef62064 \" href=\"UTD.htm?40/13/41170\">",
"     picture 2A-B",
"    </a>",
"    ). However, confident identification of such cells requires expertise in urinalysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link&amp;anchor=H10#H10\">",
"     \"Etiology and evaluation of hematuria in adults\", section on 'Glomerular versus nonglomerular bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonglomerular bleeding &mdash; In nonglomerular hematuria, the urine is typically red or pink in color. Microscopic examination demonstrates urinary RBCs with a uniform normal size and shape (",
"      <a class=\"graphic graphic_picture graphicRef80282 \" href=\"UTD.htm?43/46/44768\">",
"       picture 3",
"      </a>",
"      ). Blood clots virtually never occur with glomerular disease and are indicative of an extraglomerular source of hematuria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The procedures for obtaining and processing urine samples in children are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42886?source=see_link\">",
"     \"Urine collection techniques in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Further evaluation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Symptomatic hematuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who have symptomatic hematuria, further evaluation is guided by their clinical symptoms, history, physical examination, and urinalysis (",
"    <a class=\"graphic graphic_algorithm graphicRef68294 \" href=\"UTD.htm?3/59/4017\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trauma history &mdash; Obtain a CT scan of the abdomen and pelvis to determine the source of blood.",
"     </li>",
"     <li>",
"      Signs or symptoms of UTI &mdash; Additional findings on urinalysis suggestive of a UTI include positive dipstick tests for leukocyte esterase",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nitrite, more than five white blood cells per high-power field (spun urine), and the presence of bacteria on a Gram stain of unspun urine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An appropriately collected urine culture is obtained. If the culture is positive, treat appropriately and repeat urinalysis after the infection has cleared.",
"   </p>",
"   <p>",
"    Adenovirus should be considered as a potential etiology if urinary symptoms and urinalysis are suggestive of infection but the culture is negative [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1127/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Signs or symptoms of",
"      <span class=\"nowrap\">",
"       perineal/meatal",
"      </span>",
"      irritation &mdash; Supportive care and reassurance.",
"     </li>",
"     <li>",
"      Signs or symptoms of nephrolithiasis &mdash; The evaluation begins with imaging. Renal ultrasonography is the preferred modality in children. Abdominal plain films may be useful in identification of radiopaque stones but will miss radiolucent uric acid stones, small stones or stones overlying bony structures, and will not detect obstruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Spiral CT scan is the most sensitive imaging modality. However, because of concerns related to radiation exposure, it is not typically the initial test in young children as it is in adolescents and adults. Consultation with radiology may be warranted in younger children to determine the risk-to-benefit ratio of the test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=see_link\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Signs or symptoms suggestive of glomerular disease &mdash; Manifestations such as proteinuria, red blood cell casts, edema, and hypertension suggest a glomerular source for the hematuria. The evaluation includes serum creatinine, complete blood count, C3, C4, and serum albumin. Other tests to consider based upon the history and the physical examination include ASO titer",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      streptozyme testing to detect poststreptococcal glomerulonephritis, and antinuclear antibody testing to detect lupus nephritis. Such patients should be referred to a pediatric nephrologist (or a clinician with expertise in the care of children with renal disease).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Asymptomatic hematuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thorough diagnostic evaluation of children with asymptomatic gross hematuria is often warranted and generally leads to a diagnosis. This was illustrated in a retrospective review of 228 patients who presented to a single center for evaluation of asymptomatic gross hematuria [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1127/abstract/8\">",
"     8",
"    </a>",
"    ]. Evaluation included complete blood count, urinalysis, serum creatinine, serum C3, ultrasonography or intravenous pyelography, and renal biopsy in some cases. Etiologies for gross hematuria included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No identifiable cause &mdash; 36 percent",
"     </li>",
"     <li>",
"      Hypercalciuria &mdash; 22 percent",
"     </li>",
"     <li>",
"      IgA nephropathy &mdash;16 percent",
"     </li>",
"     <li>",
"      Post-streptococcal glomerulonephritis &mdash; 7 percent",
"     </li>",
"     <li>",
"      Other glomerulopathies including thin basement membrane disease &mdash; 2 percent",
"     </li>",
"     <li>",
"      Congenital anomalies (eg, ureteropelvic junction obstruction or renal dysplasia) &mdash; 2 percent",
"     </li>",
"     <li>",
"      Sickle cell trait &mdash; 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, left renal vein compression between the aorta and proximal superior mesenteric artery, referred to as \"nutcracker syndrome,\" has been suggested as a cause of hematuria in children that is usually asymptomatic but may be associated with left flank pain [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1127/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Nutcracker syndrome is detected by Doppler ultrasonographic assessment of left renal vein diameter and peak velocity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1127/abstract/9,11\">",
"     9,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of hematuria due to nutcracker syndrome in children appears to be highest in Asia, with the diagnosis rarely entertained in North America. This was illustrated in a Japanese case series of 85 children with hematuria without nephritis, nephrolithiasis, or tumor. Doppler ultrasonographic findings were consistent with a diagnosis of nutcracker syndrome in 21 of 23 children with gross hematuria and 17 of 52 patients with microscopic hematuria [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1127/abstract/9\">",
"     9",
"    </a>",
"    ]. Similar findings were noted in a report from Korea of 216 children with isolated microscopic or gross hematuria [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1127/abstract/10\">",
"     10",
"    </a>",
"    ]. Doppler ultrasonographic results were consistent with nutcracker syndrome in 33 percent.",
"   </p>",
"   <p>",
"    Nutcracker syndrome can also cause orthostatic proteinuria in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17655?source=see_link&amp;anchor=H274766758#H274766758\">",
"     \"Orthostatic (postural) proteinuria\", section on 'Left renal vein entrapment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children with asymptomatic gross hematuria, we suggest using the following evaluation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinalysis",
"     </li>",
"     <li>",
"      Measurement of serum creatinine and C3",
"     </li>",
"     <li>",
"      Urine culture",
"     </li>",
"     <li>",
"      Measurement of urine",
"      <span class=\"nowrap\">",
"       calcium/creatinine",
"      </span>",
"      to detect possible hypercalciuria, defined as a urine",
"      <span class=\"nowrap\">",
"       calcium/creatinine",
"      </span>",
"      ratio &gt;0.2",
"      <span class=\"nowrap\">",
"       (mg/mg)",
"      </span>",
"     </li>",
"     <li>",
"      Testing parents and siblings for hematuria (possible thin basement membrane disease or hereditary nephritis)",
"     </li>",
"     <li>",
"      Consider renal and bladder ultrasound with Doppler study to detect congenital abnormalities of the kidney or urinary tract (CAKUT), tumor, or nutcracker syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=see_link\">",
"       \"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If there is a consideration of sickle cell trait or disease, a hemoglobin electrophoresis should be obtained. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6202?source=see_link\">",
"       \"Renal manifestations of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If no diagnosis is made and hematuria persists, the patient should be referred to a pediatric nephrologist or a clinician with expertise in the care of children with renal disease. Patient referral is also recommended if there is evidence of significant renal disease (ie, hypertension, elevated serum creatinine level, proteinuria, or evidence of glomerular bleeding, such as red cell casts).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cystoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystoscopy is rarely indicated for hematuria in children. It should be reserved for the rare child with a bladder mass noted on ultrasound and those with urethral abnormalities due to trauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/51/17202?source=see_link\">",
"       \"Patient information: Blood in the urine (hematuria) in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/9/1169?source=see_link\">",
"       \"Patient information: Blood in the urine (hematuria) in children (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although gross hematuria is an uncommon occurrence in children, nevertheless it is a disturbing finding for both the affected child and",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    family.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gross hematuria is suspected when red or brown urine is present. However, red or brown urine may be due to causes other than blood, such as free hemoglobin or myoglobin, pigments from drugs (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/23/7539?source=see_link\">",
"       phenazopyridine",
"      </a>",
"      ) or foods (eg, beets), or metabolites associated with other clinical conditions (eg, porphyria). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link&amp;anchor=H4#H4\">",
"       \"Urinalysis in the diagnosis of kidney disease\", section on 'Red to brown urine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gross hematuria is distinguished from other causes of",
"      <span class=\"nowrap\">",
"       red/brown",
"      </span>",
"      urine by the a positive urinary dipstick for blood and a",
"      <span class=\"nowrap\">",
"       red/brown",
"      </span>",
"      urine sediment. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Detection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children, urinary tract infection, irritation to the meatus or perineum, and trauma are the most common causes of gross hematuria [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1127/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. Other less common causes include nephrolithiasis, sickle cell",
"      <span class=\"nowrap\">",
"       disease/trait,",
"      </span>",
"      coagulopathy, glomerular disease including postinfectious glomerulonephritis and IgA nephropathy, malignancies (eg, Wilms' tumor), and drug-induced hemorrhagic cystitis (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ). The reported relative frequency of these causes is dependent upon the clinical setting. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of symptomatic children who present with gross hematuria have an easily recognizable and apparent cause generally detected by an initial evaluation that includes a complete history, physical examination, and urinalysis (",
"      <a class=\"graphic graphic_algorithm graphicRef68294 \" href=\"UTD.htm?3/59/4017\">",
"       algorithm 2",
"      </a>",
"      ). Further testing is guided by the clinical findings of the initial evaluation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Symptomatic hematuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic evaluation of asymptomatic patients usually determines an underlying cause of hematuria and includes urinalysis, urine culture, testing family members for hematuria, ultrasonography of the kidneys and bladder, and measurements of serum creatinine, serum C3 and urine",
"      <span class=\"nowrap\">",
"       calcium/creatinine.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Asymptomatic hematuria'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1127/abstract/1\">",
"      Ingelfinger JR, Davis AE, Grupe WE. Frequency and etiology of gross hematuria in a general pediatric setting. Pediatrics 1977; 59:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1127/abstract/2\">",
"      Patel HP, Bissler JJ. Hematuria in children. Pediatr Clin North Am 2001; 48:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1127/abstract/3\">",
"      Greenfield SP, Williot P, Kaplan D. Gross hematuria in children: a ten-year review. Urology 2007; 69:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1127/abstract/4\">",
"      Youn T, Trachtman H, Gauthier B. Clinical spectrum of gross hematuria in pediatric patients. Clin Pediatr (Phila) 2006; 45:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1127/abstract/5\">",
"      Pham PT, Pham PC, Wilkinson AH, Lew SQ. Renal abnormalities in sickle cell disease. Kidney Int 2000; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1127/abstract/6\">",
"      Badenas C, Praga M, Taz&oacute;n B, et al. Mutations in theCOL4A4 and COL4A3 genes cause familial benign hematuria. J Am Soc Nephrol 2002; 13:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1127/abstract/7\">",
"      Buzza M, Wilson D, Savige J. Segregation of hematuria in thin basement membrane disease with haplotypes at the loci for Alport syndrome. Kidney Int 2001; 59:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1127/abstract/8\">",
"      Bergstein J, Leiser J, Andreoli S. The clinical significance of asymptomatic gross and microscopic hematuria in children. Arch Pediatr Adolesc Med 2005; 159:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1127/abstract/9\">",
"      Okada M, Tsuzuki K, Ito S. Diagnosis of the nutcracker phenomenon using two-dimensional ultrasonography. Clin Nephrol 1998; 49:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1127/abstract/10\">",
"      Shin JI, Park JM, Lee JS, Kim MJ. Effect of renal Doppler ultrasound on the detection of nutcracker syndrome in children with hematuria. Eur J Pediatr 2007; 166:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1127/abstract/11\">",
"      Kim SH, Cho SW, Kim HD, et al. Nutcracker syndrome: diagnosis with Doppler US. Radiology 1996; 198:93.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6108 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-113.53.254.124-160CFEADCC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_6_1127=[""].join("\n");
var outline_f1_6_1127=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DETECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Historical clues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Urinalysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Further evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Symptomatic hematuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Asymptomatic hematuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cystoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6108\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6108|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/63/23550\" title=\"algorithm 1\">",
"      Etiology of red urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?3/59/4017\" title=\"algorithm 2\">",
"      Gross hematuria algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6108|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/38/35424\" title=\"picture 1\">",
"      Photomicrograph of urine sediment with a red cell cast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/0/24591\" title=\"picture 2A\">",
"      Phase contrast micrograph showing dysmorphic red cells in urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/47/14079\" title=\"picture 2B\">",
"      Scanning electron micrograph showing dysmorphic red cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/46/44768\" title=\"picture 3\">",
"      Phase contrast micrograph showing monomorphic red cells in urine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6108|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/52/25419\" title=\"table 1\">",
"      Heme negative red urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/26/6571\" title=\"table 2\">",
"      Glomerular v extraglom in child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=related_link\">",
"      Clinical features and diagnosis of urinary tract infections in infants and children older than one month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=related_link\">",
"      Clinical manifestations and diagnosis of acute interstitial nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1337?source=related_link\">",
"      Clinical presentation and diagnosis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=related_link\">",
"      Diagnosis and acute management of suspected nephrolithiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30584?source=related_link\">",
"      Evaluation of microscopic hematuria in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27973?source=related_link\">",
"      Exercise-induced hematuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=related_link\">",
"      Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17655?source=related_link\">",
"      Orthostatic (postural) proteinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=related_link\">",
"      Overview of congenital anomalies of the kidney and urinary tract (CAKUT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/9/1169?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/51/17202?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6202?source=related_link\">",
"      Renal manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42886?source=related_link\">",
"      Urine collection techniques in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_6_1128="Sudden unexpected death in epilepsy";
var content_f1_6_1128=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sudden unexpected death in epilepsy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/6/1128/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/6/1128/contributors\">",
"     Steven C Schachter, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/6/1128/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/6/1128/contributors\">",
"     Timothy A Pedley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/6/1128/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/6/1128/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/6/1128/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with epilepsy have a small risk of sudden unexpected death, a condition referred to as sudden unexpected death in epilepsy (SUDEP) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. SUDEP is defined specifically as the sudden, unexpected, witnessed or unwitnessed, nontraumatic and nondrowning death in patients with epilepsy with or without evidence for a seizure, and excluding documented status epilepticus, in which post mortem examination does not reveal a structural or toxicologic cause for death [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cause of SUDEP is uncertain. Observations in individual cases have suggested possible cardiogenic, pulmonary, and primary neurologic etiologies. It may be that SUDEP is a heterogeneous condition.",
"   </p>",
"   <p>",
"    This topic discusses risk factors, causes, and prevention strategies for SUDEP. The management and other complications of seizures and epilepsy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2890?source=see_link\">",
"     \"Evaluation and management of drug-resistant epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16982615\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden unexpected death in epilepsy (SUDEP) is defined specifically as the sudden, unexpected, witnessed or unwitnessed, nontraumatic and nondrowning death in patients with epilepsy with or without evidence for a seizure, and excluding documented status epilepticus, in which post mortem examination does not reveal a structural or toxicologic cause for death [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;SUDEP causes between 2 and 18 percent of all deaths in patients with epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. This proportion may be somewhat higher in children, as high as 30 percent in one cohort study [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/10\">",
"     10",
"    </a>",
"    ]. The overall mean incidence is estimated at about 2 cases per 1000 patient years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/6,8,10,11\">",
"     6,8,10,11",
"    </a>",
"    ]. The incidence of SUDEP increases with severity of epilepsy, and may be as high as 0.5 to 1 percent a year in those with severe refractory epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4061626\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for SUDEP include early age of epilepsy onset, frequent generalized tonic-clonic seizures, and intractable epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/1,2,5,10,12-17\">",
"     1,2,5,10,12-17",
"    </a>",
"    ]. Case-control and cohort studies of SUDEP have identified certain clinical and demographic features as potential risk factors, although these are not all consistently found in all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/2,5,8,11,13,17-20\">",
"     2,5,8,11,13,17-20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Seizure frequency",
"      <span class=\"nowrap\">",
"       (&gt;1/month)",
"      </span>",
"     </li>",
"     <li>",
"      Medication noncompliance, subtherapeutic AED level",
"     </li>",
"     <li>",
"      Age 20 to 45 years",
"     </li>",
"     <li>",
"      Generalized tonic-clonic seizures",
"     </li>",
"     <li>",
"      Polytherapy",
"     </li>",
"     <li>",
"      Duration of epilepsy (&gt;10 years)",
"     </li>",
"     <li>",
"      Alcoholism",
"     </li>",
"     <li>",
"      Male gender",
"     </li>",
"     <li>",
"      Nocturnal seizures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most reported cases of SUDEP are in young adults, but children younger than one year can be affected [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/6,8,21-23\">",
"     6,8,21-23",
"    </a>",
"    ]. SUDEP is relatively unusual in individuals greater than 45 years. However, the latter observation may be due to under-reporting of sudden death as SUDEP in an older individual, particularly if there are medical comorbidities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;While SUDEP is only rarely witnessed, most observations suggest that SUDEP occurs in the context of a seizure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/2,3,23,24\">",
"     2,3,23,24",
"    </a>",
"    ]. While a few cases of witnessed SUDEP in the absence of clinical seizure activity have been described, subclinical seizure activity remains a possibility in these individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/16,22,25\">",
"     16,22,25",
"    </a>",
"    ]. Many SUDEP deaths occur while the patient is asleep in bed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/3,8,16,21,23\">",
"     3,8,16,21,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Possible causes of SUDEP include cardiac arrhythmia, central apnea, neurogenic pulmonary edema, and laryngospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/2,8,12,24,26-31\">",
"     2,8,12,24,26-31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cardiogenic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indirect evidence suggests that cardiogenic mechanisms may be involved in SUDEP.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some patients with epilepsy have ictal bradycardia and even asystole [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/32-35\">",
"       32-35",
"      </a>",
"      ]. Atrioventricular conduction block is a less frequently described ictal phenomenon [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/36\">",
"       36",
"      </a>",
"      ]. The frequency of this phenomenon is uncertain [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/37\">",
"       37",
"      </a>",
"      ]. One case series monitored electrocardiograms using an implantable loop recorder for an average of 18 months in 19 patients with refractory epilepsy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/38\">",
"       38",
"      </a>",
"      ]. Four patients had bradycardia or periods of asystole, prompting subsequent pacemaker placement; three of these episodes occurred during a clinical seizure. In another study, ictal asystole was observed on long-term EEG monitoring in 10 of 6825 patients (0.15 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/33\">",
"       33",
"      </a>",
"      ]. This phenomenon was not associated with cardiovascular risk factors or abnormal baseline ECG. Another series that reviewed monitoring data on 1277 seizures in 69 individuals identified five patients with ictal bradycardia occurring in 18 percent of their seizures; two of these individuals had asystolic episodes [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/35\">",
"       35",
"      </a>",
"      ]. This phenomenon is similarly unusual in children. In one case series of 49 children who had seizures on a monitoring study, ictal bradycardia occurred in 3.7 percent of seizures and only during partial complex seizures of extratemporal onset [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/39\">",
"       39",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Monitoring studies have identified clinical features that suggest an ictal arrhythmia. Diffuse atonia has been observed to accompany episodes of asystole lasting longer than eight seconds [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. Another report documented sudden falls due to seizure-induced asystole in three patients with partial epilepsy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/40\">",
"       40",
"      </a>",
"      ]. These observations suggest that when seizures include a delayed loss of tone, clinicians should consider the possibility of ictal asystole and need for cardiac monitoring. Pacemaker implantation appears to reduce falls and secondary morbidity in patients with seizure-induced asystole and bradycardia when seizures are not controlled by other therapies [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/41,42\">",
"       41,42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      While bradycardia and asystole are more commonly reported, partial seizures have been associated with tachyarrhythmias as well. In one case report, a 51 year old woman developed ictal ventricular tachycardia evolving into a ventricular fibrillation arrest requiring resuscitation [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A number of case series of combined EEG-ECG telemetry have noted prolongation of the QT interval during seizures in 12 to 23 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/44-48\">",
"       44-48",
"      </a>",
"      ]. This finding may be associated with potentially fatal ventricular arrhythmias. However, in a matched case-control study, a prolonged QT interval was not specifically associated with SUDEP [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/46\">",
"       46",
"      </a>",
"      ]. A preictal shortened QT interval has also been observed and is of uncertain clinical significance [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/47\">",
"       47",
"      </a>",
"      ]. Other ECG markers for cardiovascular arrhythmia and mortality (T-wave alternans, ventricular late potentials) have also been found to be more prevalent in patients with epilepsy compared with controls in small case series [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/49,50\">",
"       49,50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies suggest the possibility that cardiac arrhythmias may cause some cases of SUDEP [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/51\">",
"     51",
"    </a>",
"    ]. However, direct evidence of mortality from seizure-induced cardiac arrhythmias is lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/37\">",
"     37",
"    </a>",
"    ]. It is not definitely known if the risk of SUDEP is increased for patients with ictal arrhythmias compared with patients who do not have ictal changes in heart rhythm. In one study of 21 patients with SUDEP, a prior EEG-ECG recording had revealed ictal cardiac repolarization and rhythm abnormalities in 56 percent of SUDEP patients compared to 39 percent of controls [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/52\">",
"     52",
"    </a>",
"    ]. SUDEP patients also had higher ictal heart rate elevations, particularly in seizures that arose from sleep. However, this data does not indicate that routine ECG recording or ambulatory ECG monitoring can identify which epilepsy patients are at increased risk for SUDEP. One investigation observed that the cardiovascular characteristics of ictal asystole were similar to tilt-table induced vasovagal asystole [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/53\">",
"     53",
"    </a>",
"    ]. The authors speculated that ictal asystole might share a pathophysiologic mechanism with vasovagal syncope and perhaps be similarly benign.",
"   </p>",
"   <p>",
"    The etiologic link between seizures and cardiac arrhythmias and possibly sudden cardiac death is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Channelopathies (diseases caused by abnormal function of ion channels) underlie some causes of epilepsy as well as some cardiac arrhythmias. Some suggest that release of catecholamines during seizures may lead to cumulative cardiac injury (takotsubo cardiomyopathy) and possibly a susceptibility to arrhythmia or sudden hemodynamic compromise and cardiogenic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/56\">",
"     56",
"    </a>",
"    ]. The influence of antiepileptic drug treatment on SUDEP is not defined. Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    have been implicated as possibly exacerbating some of the autonomic and cardiac effects of seizures, but an increased risk of either ictal arrhythmias or SUDEP with these or other AEDs has not been defined [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/37\">",
"     37",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     Lamotrigine",
"    </a>",
"    has been identified in some reports as increasing the risk of SUDEP, possibly through a proarrhythmic effect [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/17,57\">",
"     17,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epilepsy has also been linked to cardiovascular disease. A case-control study in Stockholm found that a history of epilepsy was a risk factor for acute myocardial infarction (MI) (OR = 4.8) and was associated with a poor prognosis after MI [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/58\">",
"     58",
"    </a>",
"    ]. Other studies have also linked epilepsy and cardiovascular mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Proposed mechanisms underlying this association include an adverse effect of AEDs on cholesterol and lipid metabolism and obesity; increased smoking and decreased physical activity in persons with epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/61\">",
"     61",
"    </a>",
"    ]; as well as a possible adverse effect of chronic epilepsy upon the heart.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pulmonary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternatively, ventilatory failure with ictal hypoxemia and hypercapnia from centrally-mediated apnea may underlie some cases of SUDEP; frank apnea is sometimes observed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/25,62,63\">",
"     25,62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 56 patients with intractable epilepsy, oxygen saturation dropped below 90 percent in 33 percent of both partial and secondarily generalized seizures, below 80 percent in 10 percent of seizures, and below 70 percent in 3.6 percent of seizures [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/63\">",
"       63",
"      </a>",
"      ]. Seizure duration and temporal lobe localization were risk factors for desaturation. The timing of the apnea appeared to coincide with contralateral spread [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/64\">",
"       64",
"      </a>",
"      ]. Most apnea episodes appeared to be of central origin; 9 percent appeared obstructive. Two patients have been described with seizures whose sole or major ictal manifestation was apnea [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/25\">",
"       25",
"      </a>",
"      ]. In children, the prevalence of ictal hypoxia appears to be similar. In one case series of 225 seizures in 49 monitored children, 27 percent of seizures were associated with ictal hypoxia; in one third of these, oxygen saturation dropped below 60 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another case series of 94 recorded seizures in 33 patients revealed elevations in",
"      <span class=\"nowrap\">",
"       ictal/postictal",
"      </span>",
"      endtidal CO2 in eleven patients [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/65\">",
"       65",
"      </a>",
"      ]. Peak endtidal CO2 was above 50 mmHg in 35 seizures, above 60 mmHg in 15, and above 70 mmHg in 5 seizures. Because the degree of hypercapnia was not associated with apnea or seizure duration, the investigators speculated that it possibly resulted from ventilation-perfusion mismatch or transient pulmonary edema.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations don't clearly link apnea to SUDEP; however, in one case, a women undergoing EEG monitoring developed persistent apnea in the setting of a convulsive seizure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/29\">",
"     29",
"    </a>",
"    ]. Her cardiac rhythm remained intact initially and she underwent successful cardiopulmonary resuscitation. Another case series found that seizures associated with oxygen desaturation were also more likely to have ictal QT prolongation (OR=4.3) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternative causes of ictal respiratory compromise include laryngospasm, asphyxiation, aspiration, and neurogenic pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/54\">",
"     54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The former was observed in a single case of a 40-year-old man who developed laryngospasm with stridor and cardiopulmonary arrest during a generalized tonic clonic seizure and was successfully resuscitated [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It has been noted in some case series, although not in others, that patients with SUDEP are often found in the prone position, suggesting that asphyxiation may have played a role in their death [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/3,16,21,66\">",
"       3,16,21,66",
"      </a>",
"      ]. In a few cases of witnessed SUDEP, airway obstruction was evident [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Case series with post mortem examination often find pulmonary edema in patients with SUDEP [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/12,16,21,23\">",
"       12,16,21,23",
"      </a>",
"      ]. In one study, the prevalence of this finding was significantly higher in those with SUDEP compared to patients with epilepsy who died of an alternative cause (62 versus 27 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/16\">",
"       16",
"      </a>",
"      ]. However, the degree of edema observed is typically felt to be insufficiently severe to cause death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Neurologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden, persistent cerebral electrical silence after a seizure, suggesting a primary central nervous system mechanism, has been documented in a few cases of SUDEP [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. This may be the cause of some cases of ictal central apnea.",
"   </p>",
"   <p>",
"    In two cases of SUDEP captured on video-EEG monitoring, marked attenuation of EEG activity was followed by irregular respirations and then apnea, followed by ECG changes and asystole [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/70\">",
"     70",
"    </a>",
"    ]. A retrospective review of video-EEG telemetry studies in 10 patients who subsequently died of SUDEP found that postictal generalized EEG suppression was seen in half of these patients compared with 38 percent of seizures in control patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/71\">",
"     71",
"    </a>",
"    ]. This period of postictal EEG suppression was significantly longer in patients with SUDEP; in particular, a duration of &gt;50 seconds was associated with a significantly elevated odds of SUDEP. Other series of monitored patients without SUDEP have suggested possible pathogenic roles for this phenomenon in SUDEP. One such study found that postictal EEG suppression was associated with longer and more severe periods of postictal oxygen desaturation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/72\">",
"     72",
"    </a>",
"    ]; another correlated the duration of postictal EEG suppression with the presence and magnitude of sympathetic activation and parasympathetic suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/73\">",
"     73",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Some have suggested that brainstem serotonergic pathways may be involved in the pathogenesis of SUDEP, as they have been proposed to play a role in sudden infant death syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/74\">",
"     74",
"    </a>",
"    ]. In an animal model of SUDEP in which audiogenic seizures precipitate respiratory arrest, this phenomenon was prevented by administration of a selective serotonin reuptake inhibitor, and induced by the serotonin receptor antagonist,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/25/19862?source=see_link\">",
"     cyproheptadine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREVENTION AND COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data based on clinical trials regarding the prevention of SUDEP. Existing strategies come from knowledge of risk factors identified in cohort and case-control studies as well as expert recommendations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identifying patients at high risk, educating patients and their families about SUDEP, ascertaining seizure precipitants, and promoting compliance with treatment are strategies to reduce risk [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/2,15\">",
"       2,15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Aggressive treatment of refractory epilepsy, including referral to a comprehensive epilepsy center and consideration of epilepsy surgery, appears to be appropriate. However, SUDEP was not an outcome measure in randomized trials evaluating the efficacy of these measures. In one nonrandomized study, mortality was compared in patients who had epilepsy surgery to those who had presurgical assessment but no surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/76\">",
"       76",
"      </a>",
"      ]. Nonoperated patients were 2.4 times more likely to die as those who had surgery and were 4.5 times more likely to die a probably epilepsy-related death. In a longitudinal follow-up study of patients after temporal lobe resection, the risk for premature death decreased over time, although it remained somewhat higher than the standard population [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/77\">",
"       77",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Efforts to reduce seizure frequency with additional trials of adjunctive AEDs also seems appropriate for patients who are not surgical candidates [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/2\">",
"       2",
"      </a>",
"      ]. In a meta-analysis of placebo-controlled randomized trials in patients with refractory seizures, the risks of definite or probable SUDEP, all SUDEP, and all-cause death were lower in patients who received adjunctive AEDs in efficacious doses compared to patients in the placebo group (OR=0.17, 0.17 and 0.37, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/78\">",
"       78",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The management of drug-resistant epilepsy is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2890?source=see_link\">",
"       \"Evaluation and management of drug-resistant epilepsy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Supervision at night (defined as the supervising person sharing the same bedroom, or use of special precautions such as regular checks throughout the night, or use of a monitoring device) was associated with a decreased risk of SUDEP in a large case-control study [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/14\">",
"       14",
"      </a>",
"      ]. The efficacy of this intervention has not been confirmed in a prospective, controlled trial.",
"     </li>",
"     <li>",
"      ECG",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ECG monitoring should be considered for patients with intractable epilepsy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/37,79\">",
"       37,79",
"      </a>",
"      ]. However, this approach has not been evaluated prospectively to evaluate its impact on managing the risk of SUDEP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Informing patients about SUDEP is controversial, as there are no proven effective preventive measures [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/11\">",
"     11",
"    </a>",
"    ]. Most clinicians counsel high risk patients, particularly in the setting of risky, noncompliant behavior or when discussing the role of epilepsy surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. However, a joint task force of the American Epilepsy Society and the Epilepsy foundation and concluded that information regarding the risk of SUDEP should be disclosed to ALL patients with a diagnosis of epilepsy as part of a comprehensive education program [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/54,82\">",
"     54,82",
"    </a>",
"    ]. A survey of parents of children with epilepsy indicated that more than 90 percent though that this information should be provided to them [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/83\">",
"     83",
"    </a>",
"    ]. The potential benefits of counseling were outlined by a panel of experts and included [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1128/abstract/54\">",
"     54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Helps physicians and patients share in treatment goals",
"     </li>",
"     <li>",
"      Helps establish &ldquo;truth-telling relationship&rdquo;",
"     </li>",
"     <li>",
"      Avoids a false sense of security and complacency regarding epilepsy and its treatment",
"     </li>",
"     <li>",
"      Allows expression of patients&rsquo; anxiety about their diagnosis and encourages constructive discussion",
"     </li>",
"     <li>",
"      Allows people with epilepsy to organize their lives with reasonable expectations",
"     </li>",
"     <li>",
"      Allows people with epilepsy and caregivers to reduce potential risk factors for SUDEP, promoting compliance and minimizing behaviors that increase seizure-risk",
"     </li>",
"     <li>",
"      Reduces the fear of SUDEP in low-risk populations",
"     </li>",
"     <li>",
"      Lessens pain, grief, and blame in families in the event SUDEP does occur",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with epilepsy have a small but significant risk of sudden unexpected death (SUDEP).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most consistently observed risk factors for SUDEP are frequent convulsive seizures. (See",
"      <a class=\"local\" href=\"#H4061626\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The etiology of SUDEP is uncertain; most cases appear to occur in the context of a seizure. Theories include a cardiac arrhythmia, central apnea, or a primary central nervous system event complicating the seizure ictus. It may be that causes are heterogeneous. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiologies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no strategies that have been shown to reduce the risk of SUDEP. Maximizing seizure control is recommended, including timely consideration of epilepsy surgery.",
"     </li>",
"     <li>",
"      We suggest that clinicians counsel patients and when appropriate, family members, about SUDEP (especially patients with risk factors) to promote medical compliance and when discussing aggressive treatment of refractory epilepsy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Prevention and counseling'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/1\">",
"      Annegers JF, Coan SP. SUDEP: overview of definitions and review of incidence data. Seizure 1999; 8:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/2\">",
"      Devinsky O. Sudden, unexpected death in epilepsy. N Engl J Med 2011; 365:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/3\">",
"      Nashef L, Garner S, Sander JW, et al. Circumstances of death in sudden death in epilepsy: interviews of bereaved relatives. J Neurol Neurosurg Psychiatry 1998; 64:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/4\">",
"      Nashef L, So EL, Ryvlin P, Tomson T. Unifying the definitions of sudden unexpected death in epilepsy. Epilepsia 2012; 53:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/5\">",
"      Walczak TS, Leppik IE, D'Amelio M, et al. Incidence and risk factors in sudden unexpected death in epilepsy: a prospective cohort study. Neurology 2001; 56:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/6\">",
"      Mohanraj R, Norrie J, Stephen LJ, et al. Mortality in adults with newly diagnosed and chronic epilepsy: a retrospective comparative study. Lancet Neurol 2006; 5:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/7\">",
"      Ficker DM. Sudden unexplained death and injury in epilepsy. Epilepsia 2000; 41 Suppl 2:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/8\">",
"      Hughes JR. A review of sudden unexpected death in epilepsy: prediction of patients at risk. Epilepsy Behav 2009; 14:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/9\">",
"      Mu J, Liu L, Zhang Q, et al. Causes of death among people with convulsive epilepsy in rural West China: a prospective study. Neurology 2011; 77:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/10\">",
"      Sillanp&auml;&auml; M, Shinnar S. Long-term mortality in childhood-onset epilepsy. N Engl J Med 2010; 363:2522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/11\">",
"      Shorvon S, Tomson T. Sudden unexpected death in epilepsy. Lancet 2011; 378:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/12\">",
"      Leestma JE, Walczak T, Hughes JR, et al. A prospective study on sudden unexpected death in epilepsy. Ann Neurol 1989; 26:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/13\">",
"      Nilsson L, Farahmand BY, Persson PG, et al. Risk factors for sudden unexpected death in epilepsy: a case-control study. Lancet 1999; 353:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/14\">",
"      Langan Y, Nashef L, Sander JW. Case-control study of SUDEP. Neurology 2005; 64:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/15\">",
"      Pedley TA, Hauser WA. Sudden death in epilepsy: a wake-up call for management. Lancet 2002; 359:1790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/16\">",
"      Kloster R, Engelskj&oslash;n T. Sudden unexpected death in epilepsy (SUDEP): a clinical perspective and a search for risk factors. J Neurol Neurosurg Psychiatry 1999; 67:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/17\">",
"      Hesdorffer DC, Tomson T, Benn E, et al. Combined analysis of risk factors for SUDEP. Epilepsia 2011; 52:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/18\">",
"      Williams J, Lawthom C, Dunstan FD, et al. Variability of antiepileptic medication taking behaviour in sudden unexplained death in epilepsy: hair analysis at autopsy. J Neurol Neurosurg Psychiatry 2006; 77:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/19\">",
"      Hesdorffer DC, Tomson T, Benn E, et al. Do antiepileptic drugs or generalized tonic-clonic seizure frequency increase SUDEP risk? A combined analysis. Epilepsia 2012; 53:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/20\">",
"      Lamberts RJ, Thijs RD, Laffan A, et al. Sudden unexpected death in epilepsy: people with nocturnal seizures may be at highest risk. Epilepsia 2012; 53:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/21\">",
"      McGregor A, Wheless J. Pediatric experience with sudden unexplained death in epilepsy at a tertiary epilepsy center. J Child Neurol 2006; 21:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/22\">",
"      Donner EJ, Smith CR, Snead OC 3rd. Sudden unexplained death in children with epilepsy. Neurology 2001; 57:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/23\">",
"      Hitiris N, Suratman S, Kelly K, et al. Sudden unexpected death in epilepsy: a search for risk factors. Epilepsy Behav 2007; 10:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/24\">",
"      Langan Y, Nashef L, Sander JW. Sudden unexpected death in epilepsy: a series of witnessed deaths. J Neurol Neurosurg Psychiatry 2000; 68:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/25\">",
"      Tezer FI, R&eacute;mi J, Noachtar S. Ictal apnea of epileptic origin. Neurology 2009; 72:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/26\">",
"      Terrence CF, Rao GR, Perper JA. Neurogenic pulmonary edema in unexpected, unexplained death of epileptic patients. Ann Neurol 1981; 9:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/27\">",
"      Oppenheimer SM, Gelb A, Girvin JP, Hachinski VC. Cardiovascular effects of human insular cortex stimulation. Neurology 1992; 42:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/28\">",
"      Nei M, Ho RT, Sperling MR. EKG abnormalities during partial seizures in refractory epilepsy. Epilepsia 2000; 41:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/29\">",
"      So EL, Sam MC, Lagerlund TL. Postictal central apnea as a cause of SUDEP: evidence from near-SUDEP incident. Epilepsia 2000; 41:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/30\">",
"      Tavee J, Morris H 3rd. Severe postictal laryngospasm as a potential mechanism for sudden unexpected death in epilepsy: a near-miss in an EMU. Epilepsia 2008; 49:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/31\">",
"      Hirsch LJ. Is sudden unexpected death in epilepsy due to postictal brain shutdown? Ann Neurol 2010; 68:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/32\">",
"      Britton JW, Ghearing GR, Benarroch EE, Cascino GD. The ictal bradycardia syndrome: localization and lateralization. Epilepsia 2006; 47:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/33\">",
"      Schuele SU, Bermeo AC, Alexopoulos AV, et al. Video-electrographic and clinical features in patients with ictal asystole. Neurology 2007; 69:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/34\">",
"      Winesett P, Feliciano CA, Tatum WO 4th. Temporal lobe seizures triggering recurrent syncope by ictal asystole. Epilepsy Behav 2009; 14:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/35\">",
"      Odier C, Nguyen DK, Bouthillier A, et al. Potentially life-threatening ictal bradycardia in intractable epilepsy. Can J Neurol Sci 2009; 36:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/36\">",
"      Surges R, Scott CA, Walker MC. Peri-ictal atrioventricular conduction block in a patient with a lesion in the left insula: case report and review of the literature. Epilepsy Behav 2009; 16:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/37\">",
"      Sevcencu C, Struijk JJ. Autonomic alterations and cardiac changes in epilepsy. Epilepsia 2010; 51:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/38\">",
"      Rugg-Gunn FJ, Simister RJ, Squirrell M, et al. Cardiac arrhythmias in focal epilepsy: a prospective long-term study. Lancet 2004; 364:2212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/39\">",
"      Moseley BD, Nickels K, Britton J, Wirrell E. How common is ictal hypoxemia and bradycardia in children with partial complex and generalized convulsive seizures? Epilepsia 2010; 51:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/40\">",
"      Rubboli G, Bisulli F, Michelucci R, et al. Sudden falls due to seizure-induced cardiac asystole in drug-resistant focal epilepsy. Neurology 2008; 70:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/41\">",
"      Moseley BD, Ghearing GR, Munger TM, Britton JW. The treatment of ictal asystole with cardiac pacing. Epilepsia 2011; 52:e16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/42\">",
"      Strzelczyk A, Cenusa M, Bauer S, et al. Management and long-term outcome in patients presenting with ictal asystole or bradycardia. Epilepsia 2011; 52:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/43\">",
"      Espinosa PS, Lee JW, Tedrow UB, et al. Sudden unexpected near death in epilepsy: malignant arrhythmia from a partial seizure. Neurology 2009; 72:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/44\">",
"      Surges R, Scott CA, Walker MC. Enhanced QT shortening and persistent tachycardia after generalized seizures. Neurology 2010; 74:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/45\">",
"      Brotherstone R, Blackhall B, McLellan A. Lengthening of corrected QT during epileptic seizures. Epilepsia 2010; 51:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/46\">",
"      Surges R, Adjei P, Kallis C, et al. Pathologic cardiac repolarization in pharmacoresistant epilepsy and its potential role in sudden unexpected death in epilepsy: a case-control study. Epilepsia 2010; 51:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/47\">",
"      Surges R, Taggart P, Sander JW, Walker MC. Too long or too short? New insights into abnormal cardiac repolarization in people with chronic epilepsy and its potential role in sudden unexpected death. Epilepsia 2010; 51:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/48\">",
"      Seyal M, Pascual F, Lee CY, et al. Seizure-related cardiac repolarization abnormalities are associated with ictal hypoxemia. Epilepsia 2011; 52:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/49\">",
"      Strzelczyk A, Adjei P, Scott CA, et al. Postictal increase in T-wave alternans after generalized tonic-clonic seizures. Epilepsia 2011; 52:2112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/50\">",
"      Rejdak K, Rubaj A, G��owniak A, et al. Analysis of ventricular late potentials in signal-averaged ECG of people with epilepsy. Epilepsia 2011; 52:2118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/51\">",
"      Hirsch LJ, Hauser WA. Can sudden unexplained death in epilepsy be prevented? Lancet 2004; 364:2157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/52\">",
"      Nei M, Ho RT, Abou-Khalil BW, et al. EEG and ECG in sudden unexplained death in epilepsy. Epilepsia 2004; 45:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/53\">",
"      Schuele SU, Bermeo AC, Locatelli E, et al. Ictal asystole: a benign condition? Epilepsia 2008; 49:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/54\">",
"      Hirsch LJ, Donner EJ, So EL, et al. Abbreviated report of the NIH/NINDS workshop on sudden unexpected death in epilepsy. Neurology 2011; 76:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/55\">",
"      Lotufo PA, Valiengo L, Bense&ntilde;or IM, Brunoni AR. A systematic review and meta-analysis of heart rate variability in epilepsy and antiepileptic drugs. Epilepsia 2012; 53:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/56\">",
"      St&ouml;llberger C, Wegner C, Finsterer J. Seizure-associated Takotsubo cardiomyopathy. Epilepsia 2011; 52:e160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/57\">",
"      Aurlien D, Larsen JP, Gjerstad L, Taub&oslash;ll E. Increased risk of sudden unexpected death in epilepsy in females using lamotrigine: a nested, case-control study. Epilepsia 2012; 53:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/58\">",
"      Janszky I, Hallqvist J, Tomson T, et al. Increased risk and worse prognosis of myocardial infarction in patients with prior hospitalization for epilepsy--the Stockholm Heart Epidemiology Program. Brain 2009; 132:2798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/59\">",
"      Nilsson L, Tomson T, Farahmand BY, et al. Cause-specific mortality in epilepsy: a cohort study of more than 9,000 patients once hospitalized for epilepsy. Epilepsia 1997; 38:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/60\">",
"      Ding D, Wang W, Wu J, et al. Premature mortality in people with epilepsy in rural China: a prospective study. Lancet Neurol 2006; 5:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/61\">",
"      Hinnell C, Williams J, Metcalfe A, et al. Health status and health-related behaviors in epilepsy compared to other chronic conditions--a national population-based study. Epilepsia 2010; 51:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/62\">",
"      Blum AS, Ives JR, Goldberger AL, et al. Oxygen desaturations triggered by partial seizures: implications for cardiopulmonary instability in epilepsy. Epilepsia 2000; 41:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/63\">",
"      Bateman LM, Li CS, Seyal M. Ictal hypoxemia in localization-related epilepsy: analysis of incidence, severity and risk factors. Brain 2008; 131:3239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/64\">",
"      Seyal M, Bateman LM. Ictal apnea linked to contralateral spread of temporal lobe seizures: Intracranial EEG recordings in refractory temporal lobe epilepsy. Epilepsia 2009; 50:2557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/65\">",
"      Seyal M, Bateman LM, Albertson TE, et al. Respiratory changes with seizures in localization-related epilepsy: analysis of periictal hypercapnia and airflow patterns. Epilepsia 2010; 51:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/66\">",
"      Tao JX, Qian S, Baldwin M, et al. SUDEP, suspected positional airway obstruction, and hypoventilation in postictal coma. Epilepsia 2010; 51:2344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/67\">",
"      McLean BN, Wimalaratna S. Sudden death in epilepsy recorded in ambulatory EEG. J Neurol Neurosurg Psychiatry 2007; 78:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/68\">",
"      Lee, MA. EEG video recording of sudden unexpected death in epilepsy (SUDEP). Epilepsia 1998; 39 (Suppl 6):123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/69\">",
"      Aldenkamp AP. Effect of seizures and epileptiform discharges on cognitive function. Epilepsia 1997; 38 Suppl 1:S52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/70\">",
"      Bateman LM, Spitz M, Seyal M. Ictal hypoventilation contributes to cardiac arrhythmia and SUDEP: report on two deaths in video-EEG-monitored patients. Epilepsia 2010; 51:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/71\">",
"      Lhatoo SD, Faulkner HJ, Dembny K, et al. An electroclinical case-control study of sudden unexpected death in epilepsy. Ann Neurol 2010; 68:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/72\">",
"      Seyal M, Hardin KA, Bateman LM. Postictal generalized EEG suppression is linked to seizure-associated respiratory dysfunction but not postictal apnea. Epilepsia 2012; 53:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/73\">",
"      Poh MZ, Loddenkemper T, Reinsberger C, et al. Autonomic changes with seizures correlate with postictal EEG suppression. Neurology 2012; 78:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/74\">",
"      Benarroch EE. Brainstem respiratory chemosensitivity: new insights and clinical implications. Neurology 2007; 68:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/75\">",
"      Tupal S, Faingold CL. Evidence supporting a role of serotonin in modulation of sudden death induced by seizures in DBA/2 mice. Epilepsia 2006; 47:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/76\">",
"      Bell GS, Sinha S, Tisi Jd, et al. Premature mortality in refractory partial epilepsy: does surgical treatment make a difference? J Neurol Neurosurg Psychiatry 2010; 81:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/77\">",
"      Seymour N, Granbichler CA, Polkey CE, Nashef L. Mortality after temporal lobe epilepsy surgery. Epilepsia 2012; 53:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/78\">",
"      Ryvlin P, Cucherat M, Rheims S. Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials. Lancet Neurol 2011; 10:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/79\">",
"      Finsterer J, St&ouml;llberger C. Cardiopulmonary surveillance to prevent SUDEP. Lancet Neurol 2009; 8:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/80\">",
"      Brodie MJ, Holmes GL. Should all patients be told about sudden unexpected death in epilepsy (SUDEP)? Pros and Cons. Epilepsia 2008; 49 Suppl 9:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/81\">",
"      Beran RG, Weber S, Sungaran R, et al. Review of the legal obligations of the doctor to discuss Sudden Unexplained Death in Epilepsy (SUDEP)--a cohort controlled comparative cross-matched study in an outpatient epilepsy clinic. Seizure 2004; 13:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/82\">",
"      So EL, Bainbridge J, Buchhalter JR, et al. Report of the American Epilepsy Society and the Epilepsy Foundation joint task force on sudden unexplained death in epilepsy. Epilepsia 2009; 50:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1128/abstract/83\">",
"      Gayatri NA, Morrall MC, Jain V, et al. Parental and physician beliefs regarding the provision and content of written sudden unexpected death in epilepsy (SUDEP) information. Epilepsia 2010; 51:777.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2215 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-A67B6C3D87-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_6_1128=[""].join("\n");
var outline_f1_6_1128=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16982615\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4061626\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cardiogenic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pulmonary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Neurologic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREVENTION AND COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2890?source=related_link\">",
"      Evaluation and management of drug-resistant epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_6_1129="General approach to drug poisoning in adults";
var content_f1_6_1129=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   General approach to drug poisoning in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/6/1129/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/6/1129/contributors\">",
"     Michael J Burns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/6/1129/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/6/1129/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/6/1129/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/6/1129/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/6/1129/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accidental and intentional poisonings or drug overdoses constitute a significant source of aggregate morbidity, mortality, and health care expenditure. An estimated two to five million poisonings and drug overdoses occur annually in the United States, although the true incidence is unknown due to underdiagnosis and underreporting [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The general approach and initial management of patients with suspected or confirmed poisoning will be reviewed here. Specific issues relating to management of common drug overdoses (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    , tricyclic antidepressants, methanol) are also discussed separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the overall mortality rate from drug overdose and poison exposure is 0.05 percent, the mortality rate for hospitalized patients is approximately 1 to 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Only 5 percent of the more than two million exposures reported by poison centers in the United States in 2001 required hospital admission [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/1\">",
"     1",
"    </a>",
"    ]. However, poison exposures account for 5 to 10 percent of all emergency department visits and greater than 5 percent of adult intensive care unit (ICU) admissions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/5\">",
"     5",
"    </a>",
"    ]. The annual incidence of poisoning is increasing, with a 4.6 percent increase in cases noted between 2000 and 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Analysis of 2001 data from United States poisoning centers revealed the following statistics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      95 percent of episodes caused minor or no effects",
"     </li>",
"     <li>",
"      92 percent were due to acute rather than chronic ingestions",
"     </li>",
"     <li>",
"      92 percent involved a single substance",
"     </li>",
"     <li>",
"      85 percent were unintentional",
"     </li>",
"     <li>",
"      59 percent of poison fatalities occurred in individuals aged 20 to 49",
"     </li>",
"     <li>",
"      52 percent of exposures occurred in children younger than six years",
"     </li>",
"     <li>",
"      47 percent involved pharmaceuticals",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most commonly implicated poisoning exposures were due to analgesics (10.6 percent), cleaning substances (9.5 percent), cosmetics (9.2 percent), foreign bodies (5.1 percent), plants (4.7 percent), sedative-hypnotics and antipsychotics (4.4 percent), and cough and cold preparations (4.3 percent). Fatalities most commonly resulted from carbon monoxide poisoning or the ingestion of analgesics, sedative-hypnotics, antipsychotics, antidepressants, street drugs, cardiovascular drugs, or alcohols [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. Of note, analgesics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    , salicylate) accounted for 32 percent of fatalities from a pharmaceutical [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW OF APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians who treat poisoned patients should have a systematic and consistent approach to evaluation and management. Evaluation involves recognition that poisoning has occurred, identification of agents involved, assessment of severity, and prediction of toxicity. Management is directed to the provision of supportive care, prevention of poison absorption, and, when appropriate, the administration of antidotes and enhancement of elimination of the poison [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/7\">",
"     7",
"    </a>",
"    ]. The tempo, sequence, methods, and priorities of management are dictated by the toxin(s) involved, the presenting and predicted severity of poisoning, and the presenting phase of poisoning.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The preclinical phase follows exposure but precedes the development of signs and symptoms. Management is guided by the history and is aimed at reducing or preventing the predicted toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/8\">",
"       8",
"      </a>",
"      ]. Decontamination is a priority in this phase.",
"     </li>",
"     <li>",
"      The toxic phase encompasses the period from the onset to the peak of clinical or laboratory manifestations of toxicity. The management objectives are to shorten the duration and lessen the severity of toxicity. Treatment is guided largely by the physical examination. The highest priorities in this phase are to stabilize the patient's airway, breathing, and circulation, and to administer antidotes when indicated.",
"     </li>",
"     <li>",
"      The resolution phase runs from peak toxicity to recovery. Management is guided by clinical status, and the major goal is to shorten the duration of toxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION AND TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A brief initial screening examination should be performed on all patients to identify immediate measures required to stabilize and prevent deterioration of the patient. Vital signs, mental status, and pupil size should be rapidly assessed, and pulse oximetry, continuous cardiac monitoring, and an electrocardiogram performed. Intravenous access should be obtained, and in-line cervical immobilization is required in patients with suspected occult trauma. The airway should be assessed and endotracheal intubation strongly considered if there is doubt about the patient's ability to protect the airway and avoid aspiration. Advanced cardiac life support measures must be provided as required.",
"   </p>",
"   <p>",
"    Altered consciousness requires the rapid intravenous administration of 100 mg of thiamine and 25 g of dextrose (as 50 mL of a 50 percent dextrose solution) for possible Wernicke's encephalopathy and hypoglycemia, respectively; 0.4 to 2.0 mg of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    should also be administered to patients with signs, symptoms, or a history suggestive of opiate intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Complete exposure and examination of the patient and measurement of core temperature are essential. Patient decontamination should then be initiated (if indicated) and a more detailed diagnostic evaluation can ensue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link\">",
"     \"Gastrointestinal decontamination of poisoned adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The notion that thiamine must be given prior to dextrose to avoid precipitating Wernicke's encephalopathy is largely unsupported. Uptake of thiamine into cells is slower than that of dextrose [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/11\">",
"     11",
"    </a>",
"    ], and withholding dextrose until the administration of thiamine is complete may prove detrimental to those with actual hypoglycemia.",
"   </p>",
"   <p>",
"    Rapid reagent test strips may be used to guide dextrose administration. These strips, however, are occasionally inaccurate (eg, at both low and high blood glucose concentrations) and may be misleading (eg, clinical hypoglycemia may be present without numerical hypoglycemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/9\">",
"     9",
"    </a>",
"    ]. Empiric administration of dextrose is recommended for the patient with altered consciousness when test strip glucose measurements are low or borderline low, not immediately available, or the accuracy of their results is questioned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF POISONING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history, physical examination, and routine and toxicological laboratory evaluations are used to establish and confirm the diagnosis of poisoning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history, although intuitively the source of the most helpful information for identifying the etiology of poisoning, is often",
"    <strong>",
"     unreliable",
"    </strong>",
"    when provided by a patient following intentional ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The patient's history should be confirmed whenever possible and correlated with the signs, symptoms, and laboratory data expected from poisoning with the agent(s) implicated by history. When the patient is unable or unwilling to give a reliable history regarding poison exposure, information should be sought from paramedics, police, and the patient's employer, family, friends, primary care clinician, and pharmacist.",
"   </p>",
"   <p>",
"    A thorough search of the exposure environment should be conducted for pill bottles or a suicide note which may provide clues to etiologic agent(s). Knowledge of drugs prescribed for the patient or the patient's family or friends to which (s)he could have had access may also prove important. Unknown pills or chemicals may be identified by consultation with a regional poison control center, computerized poison identification system, or product manufacturer (eg, material data safety sheet). United States poison control centers can be reached through a toll-free line (1-800-222-1222). The World Health Organization provides a listing of international poison centers at its website (",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    ). It is critical to inquire specifically about the ingestion of over-the-counter medications, since these are often considered benign by the patient and may not be volunteered during routine questioning about \"drugs.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination of symptomatic poisoned patients may provide invaluable clues to the etiologic agent involved. The mental status, vital signs, and pupillary examination are the most useful elements and allow classification of the patient into either a state of physiologic excitation or depression [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physiologic excitation, manifested by central nervous system stimulation and increased pulse, blood pressure, respiratory rate and depth, and temperature, is most commonly caused by anticholinergic, sympathomimetic, or central hallucinogenic agents, or by drug withdrawal states.",
"     </li>",
"     <li>",
"      Physiologic depression, manifested by a depressed mental status, blood pressure, pulse, respiratory rate and depth, and temperature, is most commonly precipitated by cholinergic (parasympathomimetic), sympatholytic, opiate, or sedative-hypnotic agents, or alcohols.",
"     </li>",
"     <li>",
"      Mixed physiologic effects occur in polydrug overdoses or following exposure to certain metabolic poisons (eg, hypoglycemic agents, salicylates, cyanide), membrane-active agents (eg, volatile inhalants, antiarrhythmic drugs, local anesthetic agents), heavy metals (eg, iron, arsenic, mercury, lead), or agents with multiple mechanisms of action (eg, tricyclic antidepressants).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Following the initial diagnostic evaluation and stabilization, other physical findings should be sought to further define a particular toxic syndrome (toxidrome) and to narrow the potential etiologies of poisoning (",
"    <a class=\"graphic graphic_table graphicRef71268 \" href=\"UTD.htm?43/6/44140\">",
"     table 1",
"    </a>",
"    ). The diagnosis may be assisted by [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Characteristic odors (",
"      <a class=\"graphic graphic_table graphicRef76045 \" href=\"UTD.htm?15/17/15643\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pupillary findings (",
"      <a class=\"graphic graphic_table graphicRef61723 \" href=\"UTD.htm?3/59/4030\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Neuromuscular abnormalities (",
"      <a class=\"graphic graphic_table graphicRef64472 \" href=\"UTD.htm?27/59/28606\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mental status alterations (",
"      <a class=\"graphic graphic_table graphicRef80618 \" href=\"UTD.htm?3/52/3918\">",
"       table 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Skin findings (",
"      <a class=\"graphic graphic_table graphicRef74778 \" href=\"UTD.htm?28/51/29501\">",
"       table 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Temperature alterations (",
"      <a class=\"graphic graphic_table graphicRef55439 \" href=\"UTD.htm?32/12/32973\">",
"       table 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Blood pressure and heart rate alterations (",
"      <a class=\"graphic graphic_table graphicRef51200 \" href=\"UTD.htm?29/8/29838\">",
"       table 8",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Respiratory disturbances (",
"      <a class=\"graphic graphic_table graphicRef64012 \" href=\"UTD.htm?34/56/35725\">",
"       table 9",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Discrepancies between the physical examination and the history may reflect an inaccurate ingestion history or a brief or prolonged time interval between exposure and physical examination. The physical examination, particularly the evaluation of mental status and vital signs, should be repeated frequently to determine the course of poisoning and the need for further intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Electrocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrocardiographic abnormalities may provide diagnostic and prognostic information, and an ECG should be performed on all patients who are symptomatic or who have been exposed to potentially cardiotoxic agents (",
"    <a class=\"graphic graphic_table graphicRef66773 \" href=\"UTD.htm?23/11/23742\">",
"     table 10",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Radiographic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies are not required in every patient but may be useful in several situations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Certain radiopaque toxins (summarized by the mnemonic \"CHIPES\") may be visualized by plain film radiographs (",
"      <a class=\"graphic graphic_table graphicRef50965 \" href=\"UTD.htm?36/8/37003\">",
"       table 11",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68584 \" href=\"UTD.htm?27/43/28350\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Ingested drug packets of \"body packers\" may be seen on plain films (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef78845 \" href=\"UTD.htm?41/2/42030\">",
"       image 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12744?source=see_link\">",
"       \"Internal concealment of drugs of abuse (body packing)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some pills, particularly enteric-coated and sustained release formulations, may be visualized by abdominal ultrasound imaging [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/16,19,20\">",
"       16,19,20",
"      </a>",
"      ]. Ultrasound may be used to confirm or refute suspected ingestions, and may help determine the need for, or success of, gastrointestinal decontamination. The role of ultrasound in acute poisoning by ingestion has not yet been fully elucidated.",
"     </li>",
"     <li>",
"      Noncardiogenic pulmonary edema",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the acute respiratory distress syndrome due to exposure to certain toxic agents may be suggested by the appearance of the chest radiograph (",
"      <a class=\"graphic graphic_table graphicRef77266 \" href=\"UTD.htm?2/37/2653\">",
"       table 12",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Toxic screens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxic screening is rarely necessary when patients with a nonintentional ingestion are asymptomatic or have clinical findings that are consistent with the medical history. However, screening for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and salicylates is strongly recommended for patients with an uncertain history or intentional poisoning; few early signs may be present following lethal doses of these agents, and specific treatments are available and highly effective if implemented early. Other less common \"toxic time bombs\" for which diagnosis demands a high index of suspicion are listed in Table 13 (",
"    <a class=\"graphic graphic_table graphicRef55219 \" href=\"UTD.htm?8/2/8237\">",
"     table 13",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19913?source=see_link\">",
"     \"Salicylate (aspirin) poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    \"Drugs of abuse\" immunoassay screens can be used to detect opiates, benzodiazepines, cocaine metabolites, barbiturates, tricyclic antidepressants, tetrahydrocannabinol, and phencyclidine in urine (",
"    <a class=\"graphic graphic_table graphicRef58181 \" href=\"UTD.htm?24/57/25499\">",
"     table 14",
"    </a>",
"    ). These assays are inexpensive and provide rapid results, usually within one hour. Positive and negative screens for drugs do not absolutely confirm or refute poisoning diagnoses and require further evaluation. As an example, a negative screen may reflect a drug concentration below the threshold limit of detection due to timing of the specimen before or after peak concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=see_link\">",
"     \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to the rapid immunoassay screens, comprehensive qualitative toxic screening of urine, blood, or other body fluids (commonly by liquid and gas chromatography and mass spectrometry) is expensive, commonly requires six hours for results, often does not predict or define the severity of poisoning, detects unsuspected drugs in only a minority of patients, rarely leads to changes in patient management and disposition, and is unlikely to affect patient outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Thus, comprehensive toxic screening should be performed on blood and urine",
"    <strong>",
"     only",
"    </strong>",
"    in patients with severe or unexplained toxicity.",
"   </p>",
"   <p>",
"    Quantitative assays have defined roles in the management of poisoned patients. They are useful in guiding the management of certain intoxications when interpreted in conjunction with clinical status and the timing of poisoning (",
"    <a class=\"graphic graphic_table graphicRef63521 \" href=\"UTD.htm?21/52/22347\">",
"     table 15",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain laboratory abnormalities are characteristic of specific agents (",
"    <a class=\"graphic graphic_table graphicRef73635 \" href=\"UTD.htm?40/37/41564\">",
"     table 16",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef53698 \" href=\"UTD.htm?19/8/19598\">",
"     table 17",
"    </a>",
"    ). Symptomatic patients and those with an unreliable or unknown history should, at a minimum, undergo urinalysis and measurement of serum electrolytes, BUN, creatinine, and glucose. Measurements of serum osmolality, ketones, creatine kinase, liver function tests, amylase, calcium, and magnesium should also be performed in most significantly ill patients. Routine urine pregnancy testing is strongly recommended in all women of childbearing age.",
"   </p>",
"   <p>",
"    The ordering of other laboratory studies should be individualized and is somewhat dependent upon the results of initial laboratory studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arterial blood gas, co-oximetry, and serum lactate measurements may be necessary in patients with acid-base, cardiovascular, neurologic, or respiratory disturbances. Co-oximetry can aid in the rapid diagnosis of carbon monoxide poisoning and methemoglobinemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=see_link\">",
"       \"Carbon monoxide poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Any patient with an acid-base disturbance, increased serum osmolal gap, or oxygen saturation gap (&gt;5 percent difference between measured and calculated value) should have a toxic etiology ruled out (",
"      <a class=\"graphic graphic_table graphicRef58822 \" href=\"UTD.htm?24/3/24637\">",
"       table 18",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef62390 \" href=\"UTD.htm?6/52/6988\">",
"       table 19",
"      </a>",
"      ). Detection of a plasma osmolal gap with any alcohol intoxication occurs only when the plasma osmolality is measured by",
"      <strong>",
"       freezing point depression",
"      </strong>",
"      ; the osmotic contribution of volatile alcohols is not included when using a vapor pressure osmometer, which assumes that only water is in the vapor phase. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41430?source=see_link\">",
"       \"Serum osmolal gap\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of an anion gap metabolic acidosis may be the first clue to a toxic ingestion and should prompt measurement of serum salicylates, ethylene glycol, and methanol and examination of the urine for oxalate crystals; serum creatinine, glucose, ketones, and lactate also should be measured to detect other causes of the high gap acidosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link\">",
"       \"Approach to the adult with metabolic acidosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4154?source=see_link\">",
"       \"Methanol and ethylene glycol poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of an abnormally elevated serum creatinine with a normal BUN may be seen with isopropyl alcohol poisoning (or with diabetic ketoacidosis). High serum levels of acetone, which are formed as a metabolite of isopropyl alcohol, interfere with colorimetric creatinine assays, resulting in falsely elevated values [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Measurement of isopropyl alcohol concentration in blood should be obtained in patients with an elevated osmolal gap without metabolic acidosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/60/20423?source=see_link\">",
"       \"Isopropyl alcohol poisoning\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     POISONING MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal management of the poisoned patient depends upon the specific poison(s) involved, the presenting and predicted severity of illness, and elapsed time between exposure and presentation. Treatment variably includes supportive care, decontamination, antidotal therapy, and enhanced elimination techniques. Assistance can be obtained from regional poison control centers. United States poison control centers can be reached through a toll-free line (1-800-222-1222). The World Health Organization provides a listing of international poison centers at its website (",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following initial patient stabilization, patient decontamination may be performed if indicated. The sooner decontamination is performed, the more effective it is at preventing poison absorption. Copious water or saline irrigation for topical exposures and administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    for ingestions are the preferred methods of decontamination. In certain circumstances, other methods of gastrointestinal decontamination may be warranted, such as gastric lavage, whole bowel irrigation, endoscopy, surgery, dilution, and cathartics. The role of decontamination in the management of specific toxins is reviewed in topics devoted the poisoning in question; general discussions of methods for decontamination, including the evidence for their effectiveness, are found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link\">",
"     \"Gastrointestinal decontamination of poisoned adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26695?source=see_link\">",
"     \"Enhanced elimination of poisons\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Antidotes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidote administration is appropriate when there is a poisoning for which an antidote exists, the actual or predicted severity of poisoning warrants its use, expected benefits of therapy outweigh its associated risk, and there are no contraindications. Antidotes dramatically reduce morbidity and mortality in certain intoxications, but they are unavailable for most toxic agents and therefore are used in only about 1 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antidotes reduce or reverse poison effects by a variety of means. They may prevent absorption, bind and neutralize poisons directly, antagonize end-organ effects, or inhibit conversion to more toxic metabolites.",
"   </p>",
"   <p>",
"    The pharmacokinetics of the intoxicant and the antidote must be considered because the toxidrome may recur if the antidote is eliminated more rapidly than the ingested substance, particularly if the antidote acts by antagonizing end-organ effects or inhibiting conversion to toxic metabolites. As an example, somnolence and respiratory depression due to ingested opiates acutely reverse with the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    but recur in approximately one-third of cases because the elimination half-life of naloxone is only 60 to 90 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/10,24\">",
"     10,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=see_link\">",
"     \"Opioid intoxication in adults\"",
"    </a>",
"    .) Thus, in certain situations antidotes may require repeated administration or continuous infusion.",
"   </p>",
"   <p>",
"    Although a response to empirically administered antidotes can be used to confirm a suspected diagnosis, their indiscriminate use can potentially increase patient morbidity. As an example, routine administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/6/41062?source=see_link\">",
"     flumazenil",
"    </a>",
"    to comatose patients suspected of benzodiazepine overdose may precipitate seizures and worsen the clinical course if tricyclic antidepressants have been coingested. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36231?source=see_link\">",
"     \"Tricyclic antidepressant poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Enhanced elimination techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Procedures to enhance elimination of poisons include forced diuresis, urine ion trapping, hemodialysis, hemoperfusion, hemofiltration, and exchange transfusion. Various measures are useful in selected circumstances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26695?source=see_link\">",
"     \"Enhanced elimination of poisons\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care is the most important aspect of treatment and, when coupled with decontamination, frequently is sufficient to effect complete patient recovery. Supportive care for the poisoned patient is generally similar to that utilized for other critically ill patients, but certain issues are managed slightly differently:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Airway protection by endotracheal intubation should be performed early in the poisoned patient with depressed mental status because of the high risk for aspiration and its associated complications, particularly when gastric decontamination procedures need to be undertaken [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/25\">",
"       25",
"      </a>",
"      ]. Endotracheal intubation with mechanical ventilation is also indicated in the presence of severe acid-base disturbances or acute respiratory failure. Occasionally, the management of high-grade physiologic stimulation may require sedation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      paralysis with mechanical ventilation to limit the extent of complications such as hyperthermia, acidosis, and rhabdomyolysis.",
"     </li>",
"     <li>",
"      Hypotension should be managed initially with intravenous fluids. Vasopressors are required when hypotension does not resolve with volume expansion. Direct-acting vasopressors, such as norepinephrine, have been shown to be more effective than indirect-acting agents, such as dopamine, when tricyclic antidepressants have been ingested [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36231?source=see_link\">",
"       \"Tricyclic antidepressant poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypertension in agitated patients is best treated initially with nonspecific sedatives such as a benzodiazepine [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/28\">",
"       28",
"      </a>",
"      ]. When hypertension necessitates specific therapy because of associated end-organ dysfunction, preferred treatments are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      or other calcium-channel blockers,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"       phentolamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"       labetalol",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      . The use of beta-blockers alone for patients with sympathetic hyperactivity (eg, cocaine intoxication) is",
"      <strong>",
"       not",
"      </strong>",
"      recommended because it may result in unopposed alpha-adrenergic stimulation and intensified vasoconstriction [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. The combination of a beta-blocker with a vasodilator (eg, nitroprusside) is acceptable in these circumstances.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       Sodium bicarbonate",
"      </a>",
"      is first line therapy for ventricular tachycardias when they occur in the context of intoxication with tricyclic antidepressants or other membrane-active agents. Types IA (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      ), IC, and III antiarrhythmic agents are",
"      <strong>",
"       not",
"      </strong>",
"      recommended and are potentially dangerous since they may further impair cardiac conduction.",
"      <br/>",
"      <br/>",
"      The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      for the treatment of drug-associated ventricular tachycardia is controversial. While phenytoin appeared beneficial in one animal model of cyclic antidepressant poisoning [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/30\">",
"       30",
"      </a>",
"      ], it increased the incidence and duration of ventricular tachycardia in another [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/31\">",
"       31",
"      </a>",
"      ]. Anecdotally, phenytoin has been safely used for drug-associated ventricular tachycardia and conduction abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. Negative inotropic effects (from the propylene glycol diluent) may outweigh any potential benefit. The effectiveness and safety of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/51/14138?source=see_link\">",
"       fosphenytoin",
"      </a>",
"      has not been studied. Although likely safe, we do not recommend the use of phenytoin for drug-associated ventricular tachycardias or conduction abnormalities.",
"      <br/>",
"      <br/>",
"      Overdrive pacing with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"       isoproterenol",
"      </a>",
"      or a temporary pacemaker may be effective in patients with drug-induced torsades de pointes and prolonged QT intervals on ECG. Digoxin-poisoned patients with life-threatening tachyarrhythmias or bradyarrhythmias should be treated with specific Fab fragments (Digibind). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"       \"Acquired long QT syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/13/25817?source=see_link\">",
"       \"Digitalis (cardiac glycoside) poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bradyarrhythmias associated with hypotension should be treated in the standard fashion with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      or temporary pacing. However, in patients with calcium channel blocker or beta blocker intoxication, the administration of calcium and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"       glucagon",
"      </a>",
"      may obviate the need for further measures [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/34-37\">",
"       34-37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31736?source=see_link\">",
"       \"Calcium channel blocker poisoning\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=see_link\">",
"       \"Major side effects of beta blockers\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Seizures generally are best treated with benzodiazepines followed by barbiturates if necessary.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       Phenytoin",
"      </a>",
"      may be effective in controlling seizures caused by agents which stabilize neuronal membranes (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      ), but is not indicated and is potentially harmful in seizures resulting from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/38\">",
"       38",
"      </a>",
"      ]. Seizures caused by certain agents may require specific antidotes for their successful termination (eg, pyridoxine for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      toxicity, glucose for hypoglycemic agents).",
"     </li>",
"     <li>",
"      Drug-associated agitated behavior is generally best treated with benzodiazepine administration, supplemented with high potency neuroleptics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      ) as needed [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/39\">",
"       39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15833?source=see_link\">",
"       \"Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal\"",
"      </a>",
"      .) Agitation associated with certain toxidromes may be best treated with specific agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40372?source=see_link\">",
"       physostigmine",
"      </a>",
"      for the anticholinergic syndrome) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following initial evaluation, treatment, and a short period of observation, disposition of the patient is based upon the observed and predicted severity of toxicity. Patients who develop only mild toxicity and who have only a low predicted severity can be observed in the emergency department until they are asymptomatic. An observation period of four to six hours is usually adequate for this purpose. Patients with moderate observed toxicity or those who are at risk for such on the basis of history or initial laboratory data should be admitted to an intermediate-care floor or an appropriate observation unit for continued monitoring and treatment. Patients with significant toxicity should be admitted to an ICU (",
"    <a class=\"graphic graphic_table graphicRef81467 \" href=\"UTD.htm?6/61/7132\">",
"     table 20",
"    </a>",
"    ).",
"    <strong>",
"     All",
"    </strong>",
"    patients with intentional overdose require psychiatric assessment prior to discharge.",
"   </p>",
"   <p>",
"    One retrospective study of 209 patients with drug overdoses suggested that clinical assessment in the emergency department could reliably identify patients who are at high risk for complications and require ICU care [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1129/abstract/41\">",
"     41",
"    </a>",
"    ]. The presence of any of eight clinical criteria predicted a complicated hospital course that could be best managed in an ICU:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      PaCO2 &gt;45 mmHg",
"     </li>",
"     <li>",
"      A need for emergency intubation",
"     </li>",
"     <li>",
"      The presence of postingestion seizures",
"     </li>",
"     <li>",
"      Unresponsiveness to verbal stimuli",
"     </li>",
"     <li>",
"      A non-sinus cardiac rhythm",
"     </li>",
"     <li>",
"      Second- or third-degree atrioventricular block",
"     </li>",
"     <li>",
"      Systolic blood pressure less than 80 mmHg",
"     </li>",
"     <li>",
"      QRS duration &ge;0.12 seconds",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    None of the 151 patients who lacked these risk factors developed a high-risk condition after admission and none required transfer to the ICU. The authors estimated that use of these predictors in similar patient populations could eliminate over one-half of intensive care days for poisoning without compromising the quality of care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11202577\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While poisonings can be fatal, the vast majority of patients presenting with a toxic exposure suffer minimal morbidity and recover fully. As a result, it is important to weigh the risks of interventions against the potential benefits which, for many patients, are relatively small. Assistance can be obtained from regional poison control centers. United States poison control centers can be reached through a toll-free line (1-800-222-1222). The World Health Organization provides a listing of international poison centers at its website (",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The essential elements of care for the poisoned patient include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Institute stabilization procedures in patients with a compromised airway, inadequate gas exchange, or marginal hemodynamics. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Initial evaluation and treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obtain a thorough history of actual and potential exposures. Utilize information from friends, family, and prehospital personnel when available. Always inquire specifically about the use of over-the-counter drugs in cases of intentional overdose. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Perform a thorough physical examination to ascertain signs of a potential toxidrome as well as complications of the toxic exposure. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obtain a focused laboratory and radiographic evaluation that is guided by the severity of the patient's clinical status and the suspected toxins. Symptomatic patients and those with an unknown or unreliable history should, at a minimum, have measurements of serum electrolytes, renal function, and blood glucose. A urinalysis should also be performed. Calculation of the osmolal and anion gaps will help guide further evaluation of the toxic agent. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Radiographic studies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Other laboratory studies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Electrocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obtain a \"toxic screen\" of blood",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      urine in patients with severe or unexplained toxicity. Limited immunoassay screens are adequate for most cases of intentional overdose and provide less expensive and more timely results than comprehensive qualitative assays using gas chromatography or mass spectrometry. Screening for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      and salicylates is strongly recommended for patients with an uncertain history, intentional poisoning, or unexplained toxicity. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Toxic screens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obtain quantitative drug levels if such levels will help guide management.",
"     </li>",
"     <li>",
"      Obtain a pregnancy test in women of child-bearing age.",
"     </li>",
"     <li>",
"      Supportive care in conjunction with decontamination procedures is sufficient for the vast majority of patients with toxic exposures. The decision to admit a patient with a toxic exposure to an ICU should be based upon clinical criteria that relate to the stability of the airway, respiratory system, cardiovascular system, and the patient's level of consciousness. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Poisoning management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Disposition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/1\">",
"      Litovitz TL, Klein-Schwartz W, Rodgers GC Jr, et al. 2001 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2002; 20:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/2\">",
"      McCaig LF, Burt CW. Poisoning-related visits to emergency departments in the United States, 1993-1996. J Toxicol Clin Toxicol 1999; 37:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/3\">",
"      Henderson A, Wright M, Pond SM. Experience with 732 acute overdose patients admitted to an intensive care unit over six years. Med J Aust 1993; 158:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/4\">",
"      Tibbalis, J. Epidemiology of acute poisoning. Med Int 1989; 61:2496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/5\">",
"      Proudfoot, A. Acute poisoning: Principles of management. Med Int 1989; 61:2499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/6\">",
"      Cobb N, Etzel RA. Unintentional carbon monoxide-related deaths in the United States, 1979 through 1988. JAMA 1991; 266:659.",
"     </a>",
"    </li>",
"    <li>",
"     Linden CH. General considerations in the evaluation and treatment of poisoning. In: Intensive Care Medicine, Rippe JM, Irwin RS, Fink MP, Cerra FB.  (Eds), Little Brown and Company, Boston 1996. p.1455.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/8\">",
"      Spyker DA, Minocha A. Toxicodynamic approach to management of the poisoned patient. J Emerg Med 1988; 6:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/9\">",
"      Hoffman RS, Goldfrank LR. The poisoned patient with altered consciousness. Controversies in the use of a 'coma cocktail'. JAMA 1995; 274:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/10\">",
"      Sporer KA. Acute heroin overdose. Ann Intern Med 1999; 130:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/11\">",
"      Tate JR, Nixon PF. Measurement of Michaelis constant for human erythrocyte transketolase and thiamin diphosphate. Anal Biochem 1987; 160:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/12\">",
"      Soslow AR. Acute drug overdose: one hospital's experience. Ann Emerg Med 1981; 10:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/13\">",
"      Wright N. An assessment of the unreliability of the history given by self-poisoned patients. Clin Toxicol 1980; 16:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/14\">",
"      Olson KR, Pentel PR, Kelley MT. Physical assessment and differential diagnosis of the poisoned patient. Med Toxicol 1987; 2:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/15\">",
"      Savitt DL, Hawkins HH, Roberts JR. The radiopacity of ingested medications. Ann Emerg Med 1987; 16:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/16\">",
"      Kurt TL, Anderson RJ, Reed WG. Rapid estimation of carboxyhemoglobin by breath sampling in an emergency setting. Vet Hum Toxicol 1990; 32:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/17\">",
"      McCarron MM, Wood JD. The cocaine 'body packer' syndrome. Diagnosis and treatment. JAMA 1983; 250:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/18\">",
"      Traub SJ, Hoffman RS, Nelson LS. Body packing--the internal concealment of illicit drugs. N Engl J Med 2003; 349:2519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/19\">",
"      Amitai Y, Silver B, Leikin JB, Frischer H. Visualization of ingested medications in the stomach by ultrasound. Am J Emerg Med 1992; 10:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/20\">",
"      Florez MV, Evans JM, Daly TR. The radiodensity of medications seen on x-ray films. Mayo Clin Proc 1998; 73:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/21\">",
"      Brett AS. Implications of discordance between clinical impression and toxicology analysis in drug overdose. Arch Intern Med 1988; 148:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/22\">",
"      Kellermann AL, Fihn SD, LoGerfo JP, Copass MK. Impact of drug screening in suspected overdose. Ann Emerg Med 1987; 16:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/23\">",
"      Hawley PC, Falko JM. \"Pseudo\" renal failure after isopropyl alcohol intoxication. South Med J 1982; 75:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/24\">",
"      Watson WA, Steele MT, Muelleman RL, Rush MD. Opioid toxicity recurrence after an initial response to naloxone. J Toxicol Clin Toxicol 1998; 36:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/25\">",
"      Isbister GK, Downes F, Sibbritt D, et al. Aspiration pneumonitis in an overdose population: frequency, predictors, and outcomes. Crit Care Med 2004; 32:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/26\">",
"      Tran TP, Panacek EA, Rhee KJ, Foulke GE. Response to dopamine vs norepinephrine in tricyclic antidepressant-induced hypotension. Acad Emerg Med 1997; 4:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/27\">",
"      Buchman AL, Dauer J, Geiderman J. The use of vasoactive agents in the treatment of refractory hypotension seen in tricyclic antidepressant overdose. J Clin Psychopharmacol 1990; 10:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/28\">",
"      Hollander JE. The management of cocaine-associated myocardial ischemia. N Engl J Med 1995; 333:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/29\">",
"      Lange RA, Cigarroa RG, Flores ED, et al. Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med 1990; 112:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/30\">",
"      Kulig, K, Bar-Or, D, Wythe, E, Rumack, BH. Phenytoin as treatment for tricyclic antidepressant cardiotoxicity in a canine model. Vet Hum Toxicol 1984; 26:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/31\">",
"      Callaham M, Schumaker H, Pentel P. Phenytoin prophylaxis of cardiotoxicity in experimental amitriptyline poisoning. J Pharmacol Exp Ther 1988; 245:216.",
"     </a>",
"    </li>",
"    <li>",
"     Mayron R, Ruiz E. Tricyclin antidepressant overdose: Cardiac conduction abnormalities and the use of phenytoin for treatment. EMS Stat MD 1986; 341.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/33\">",
"      Mayron R, Ruiz E. Phenytoin: does it reverse tricyclic-antidepressant-induced cardiac conduction abnormalities? Ann Emerg Med 1986; 15:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/34\">",
"      Kenny J. Treating overdose with calcium channel blockers. BMJ 1994; 308:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/35\">",
"      Yuan TH, Kerns WP 2nd, Tomaszewski CA, et al. Insulin-glucose as adjunctive therapy for severe calcium channel antagonist poisoning. J Toxicol Clin Toxicol 1999; 37:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/36\">",
"      Kline JA, Tomaszewski CA, Schroeder JD, Raymond RM. Insulin is a superior antidote for cardiovascular toxicity induced by verapamil in the anesthetized canine. J Pharmacol Exp Ther 1993; 267:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/37\">",
"      Kerns W 2nd, Schroeder D, Williams C, et al. Insulin improves survival in a canine model of acute beta-blocker toxicity. Ann Emerg Med 1997; 29:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/38\">",
"      Blake KV, Massey KL, Hendeles L, et al. Relative efficacy of phenytoin and phenobarbital for the prevention of theophylline-induced seizures in mice. Ann Emerg Med 1988; 17:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/39\">",
"      Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997; 15:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/40\">",
"      Burns MJ, Linden CH, Graudins A, et al. A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med 2000; 35:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1129/abstract/41\">",
"      Brett AS, Rothschild N, Gray R, Perry M. Predicting the clinical course in intentional drug overdose. Implications for use of the intensive care unit. Arch Intern Med 1987; 147:133.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 324 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-9372CC6D8A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_6_1129=[""].join("\n");
var outline_f1_6_1129=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW OF APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INITIAL EVALUATION AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS OF POISONING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Electrocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Radiographic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Toxic screens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      POISONING MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Antidotes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Enhanced elimination techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11202577\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/324\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/324|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/43/28350\" title=\"diagnostic image 1\">",
"      Ferrous sulfate overdose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/2/42030\" title=\"diagnostic image 2\">",
"      Drug packet ingestion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/324|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/6/44140\" title=\"table 1\">",
"      Poisoning syndromes - toxidromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/17/15643\" title=\"table 2\">",
"      Drug and toxin associated odors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/59/4030\" title=\"table 3\">",
"      Drug and toxin induced ocular findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/59/28606\" title=\"table 4\">",
"      Drug and toxin related movement disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/52/3918\" title=\"table 5\">",
"      Drug and toxin induced mental status changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/51/29501\" title=\"table 6\">",
"      Drug and toxin related skin findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/12/32973\" title=\"table 7\">",
"      Drug and toxin related temperature change",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/8/29838\" title=\"table 8\">",
"      Drug and toxin related pulse changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/56/35725\" title=\"table 9\">",
"      Drug and toxin related respiratory change",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/11/23742\" title=\"table 10\">",
"      Drug and toxin induced ECG abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/8/37003\" title=\"table 11\">",
"      Radiopaque toxins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/37/2653\" title=\"table 12\">",
"      Drug and toxin related pulmonary edema or pneumonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/2/8237\" title=\"table 13\">",
"      Delayed clinical toxicity agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/57/25499\" title=\"table 14\">",
"      Urine test drugs of abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/52/22347\" title=\"table 15\">",
"      Quantitative drug levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/37/41564\" title=\"table 16\">",
"      Drug and toxin related electrolyte change",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/8/19598\" title=\"table 17\">",
"      Drug and toxin related laboratory changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/3/24637\" title=\"table 18\">",
"      Drug and toxin related anion gap changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/52/6988\" title=\"table 19\">",
"      Increased osmolal and O2 gaps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/61/7132\" title=\"table 20\">",
"      Poisoned patient ICU criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=related_link\">",
"      Approach to the adult with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31736?source=related_link\">",
"      Calcium channel blocker poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=related_link\">",
"      Carbon monoxide poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/13/25817?source=related_link\">",
"      Digitalis (cardiac glycoside) poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26695?source=related_link\">",
"      Enhanced elimination of poisons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=related_link\">",
"      Gastrointestinal decontamination of poisoned adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12744?source=related_link\">",
"      Internal concealment of drugs of abuse (body packing)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/60/20423?source=related_link\">",
"      Isopropyl alcohol poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4154?source=related_link\">",
"      Methanol and ethylene glycol poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=related_link\">",
"      Opioid intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19913?source=related_link\">",
"      Salicylate (aspirin) poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15833?source=related_link\">",
"      Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41430?source=related_link\">",
"      Serum osmolal gap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36231?source=related_link\">",
"      Tricyclic antidepressant poisoning",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_6_1130="Acute mountain sickness and high altitude cerebral edema";
var content_f1_6_1130=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute mountain sickness and high altitude cerebral edema",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/6/1130/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/6/1130/contributors\">",
"     Scott A Gallagher, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/6/1130/contributors\">",
"     Peter Hackett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/6/1130/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/6/1130/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/6/1130/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/6/1130/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/6/1130/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anyone who travels to high altitude, whether a recreational hiker, professional mountain climber, or rescue worker, is at risk of developing high altitude illness. Acute mountain sickness (AMS) and high altitude cerebral edema (HACE) represent a continuum of one form of such illness.",
"   </p>",
"   <p>",
"    The pathophysiology, clinical presentation, treatment, and prevention of AMS and HACE are reviewed here. Other forms of high altitude illness are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28936?source=see_link\">",
"     \"High altitude pulmonary edema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=see_link\">",
"     \"High altitude illness: Physiology, risk factors, and general prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute mountain sickness (AMS) and high altitude cerebral edema (HACE) are generally considered to represent two points along a single spectrum of disease, with the same underlying pathophysiology. Although several aspects of this pathophysiology remain unclear, the concept that",
"    <span class=\"nowrap\">",
"     AMS/HACE",
"    </span>",
"    represents a continuum, and that AMS can progress to fatal HACE, fits with clinical experience and is helpful for management. A full discussion of the pathophysiology of AMS and HACE is beyond the scope of this review, but may be found in the attached references [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cerebral edema is consistently found in neuroimaging and at autopsy in patients with severe AMS or HACE [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]. MRI studies reveal reversible vasogenic brain edema, with characteristic T2 signal increase in the splenium of the corpus callosum and subcortical white matter. These findings indicate increased blood-brain barrier (BBB) permeability.",
"   </p>",
"   <p>",
"    Some hypotheses to explain this increased cerebral vascular permeability emphasize the role of increased intravascular pressure. Increased cerebral blood flow and the loss of autoregulation of intracranial pressure may contribute to such an increase. Chemical factors (eg, vascular endothelial growth factor, nitric oxide, cytokines) may also play a role by altering endothelial permeability [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Survivors of HACE demonstrate microhemorrhages on MRI, evidenced by deposits of hemosiderin in the corpus callosum, which are not found in those with AMS (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53871 \" href=\"UTD.htm?11/61/12244\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/7\">",
"     7",
"    </a>",
"    ]. Brain herniation from severely increased ICP is the cause of death in HACE. Fatal cases demonstrate not only gross cerebral edema, but small petechial hemorrhages and sometimes venous sinus or other thromboses [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship between cerebral edema and mild to moderate AMS is less clear. There is evidence of mild extravascular water (vasogenic edema) and increased brain tissue volume from vasodilation in all persons exposed to hypoxic environments, irrespective of AMS. However, subjects with mild AMS may not demonstrate greater brain swelling on MRI than those without symptoms. Therefore, mild edema alone is unlikely to be responsible for the clinical manifestations of mild to moderate AMS [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The \"tight fit\" hypothesis suggests that it is not the amount of swelling that matters as much as the person's ability to tolerate such swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/11\">",
"     11",
"    </a>",
"    ]. In other words, individuals with a greater brain to cranial vault ratio (ie, less room for the swollen brain) become more symptomatic than individuals with a smaller ratio (ie, more room) but with the same degree of cerebral edema.",
"   </p>",
"   <p>",
"    Some believe that activation of the trigeminal vascular system, in a manner similar to migraine, may play a role in AMS [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     AMS epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute mountain sickness (AMS) is by far the most common high altitude illness (HAI). As with all HAI, the risk of AMS depends upon individual susceptibility, the elevation reached, and the rate of ascent. Thus, while AMS is uncommon below 2000 m (6500 ft), it is quite common (approximately 25 percent incidence) at sleeping elevations between 2000 and 3000 m, where the majority of ski resorts in the United States are located (",
"    <a class=\"graphic graphic_table graphicRef63999 \" href=\"UTD.htm?8/24/8588\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef50199 \" href=\"UTD.htm?0/4/71\">",
"     table 2",
"    </a>",
"    ). Recreational skiers traveling to such resorts generally complete their transition to high altitude quickly (within two days) further increasing their risk of AMS.",
"   </p>",
"   <p>",
"    AMS is nearly universal (85 percent incidence) among those flying directly to Shyangboche, Nepal (elevation 3800 m) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/13\">",
"     13",
"    </a>",
"    ]. It occurs in 67 percent of climbers taking one to two days to reach the summit of Mount Rainier (4392 m) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/14\">",
"     14",
"    </a>",
"    ], but strikes only 30 percent of climbers taking approximately one week to reach the summit of Denali (6194 m) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/15\">",
"     15",
"    </a>",
"    ]. Conversely, the incidence of AMS is negligible among individuals who remain at altitude only an hour or two after driving to Pikes Peak (elevation 4300 m) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AMS occurs in both genders and at all ages, although the incidence is decreased among those 50 to 60 years or older [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. Women may be at slightly higher risk than men, but children and adults are both susceptible [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/17,20-22\">",
"     17,20-22",
"    </a>",
"    ]. HAI in children is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27769?source=see_link\">",
"     \"High altitude disease: Unique pediatric considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neither youth nor physical fitness confers protection against AMS. Obesity, heavy exertion upon arrival at altitude, and residence at low altitude prior to ascent all appear to increase risk [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/5,23\">",
"     5,23",
"    </a>",
"    ]. However, smoking, oral contraceptives, and menstruation do not appear to increase risk [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/17\">",
"     17",
"    </a>",
"    ]. A more detailed discussion of the risk factors for HAI generally is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=see_link\">",
"     \"High altitude illness: Physiology, risk factors, and general prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     HACE epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of HACE is reported to be 0.1 to 2 percent at elevations in excess of 3000 to 4000 m (9800 to 13,000 ft), although HACE has been reported at altitudes as low as 2100 m [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. HACE is often complicated by concomitant HAPE. In fact, pure cerebral edema without pulmonary edema appears to be uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HACE appears to occur in all ages and both genders in a fashion similar to AMS. Younger males may be at greater risk for behavioral reasons, such as continuing to climb in the presence of AMS symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with AMS, there are no physiologic, anatomic, or genetic characteristics that reliably predict susceptibility to HACE. Individuals with a history of AMS or HAPE are at greater risk of recurrence and of developing HACE [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PRESENTATION AND DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     AMS diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute mountain sickness (AMS) is diagnosed clinically based upon the appearance of typical symptoms in a person who lives at low altitude, but has recently ascended to high altitude (generally over 2000 m).",
"   </p>",
"   <p>",
"    Symptoms in adults resemble those of an alcohol hangover: primarily headache, which is often associated with fatigue, lightheadedness, anorexia, nausea and vomiting, disturbed sleep with frequent awakening, and mild shortness of breath with exertion. Symptoms may be mild or severely debilitating.",
"   </p>",
"   <p>",
"    Symptoms of AMS in infants and young children are nonspecific and can include fussiness, crying, decreased playfulness, poor feeding, disrupted sleep, and possibly vomiting. AMS alone does not cause an elevation in body temperature and an appropriate evaluation for fever based upon age and immunization status is warranted in febrile children at altitude. AMS is often a diagnosis of exclusion in this group. The clinician should pay close attention to the child's signs and response to oxygen, and when in doubt should err on the side of a longer observation period before attributing symptoms to a benign cause. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27769?source=see_link&amp;anchor=H5#H5\">",
"     \"High altitude disease: Unique pediatric considerations\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The onset of AMS is usually delayed for 6 to 12 hours following arrival at high altitude, but can occur as rapidly as 1 to 2 hours or as late as 24 hours. Symptoms are often most severe after the first night, generally resolve in one day if there is no further ascent, and do not recur at the same altitude.",
"   </p>",
"   <p>",
"    AMS may reappear upon ascent to higher altitudes. On occasion, symptoms of AMS may persist for weeks despite no further ascent. In such cases, descent is required if there is no improvement with standard treatment. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'AMS treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are no reliable objective measures for the diagnosis of AMS. Physical examination, laboratory values, vital signs, and pulse oximetry typically fall within the normal range. Clinical studies often employ a scoring system (eg, Lake Louise) for diagnosis (",
"    <a class=\"graphic graphic_table graphicRef74655 \" href=\"UTD.htm?41/23/42364\">",
"     table 3",
"    </a>",
"    ). Diagnosis may be straightforward in a young, otherwise healthy individual who has recently ascended to high altitude. However, diagnosis may be difficult in the elderly, young children, and those with confounding illness.",
"   </p>",
"   <p>",
"    Supplemental oxygen may be used to support the clinical diagnosis. Providing 2 to 4",
"    <span class=\"nowrap\">",
"     L/minute",
"    </span>",
"    of oxygen by nasal cannula for 15 to 20 minutes prior to other interventions should markedly improve headache and other symptoms in cases of AMS.",
"   </p>",
"   <p>",
"    The onset of symptoms more than two days after arrival at a given altitude, absence of headache, dyspnea at rest, and failure to improve rapidly with supplemental oxygen should prompt the clinician to search for an alternative diagnosis. No radiographic or laboratory testing is warranted, unless the diagnosis is unclear. Differential diagnoses to consider include carbon monoxide poisoning, migraine, dehydration, exhaustion, hyponatremia, viral syndrome, alcohol hangover, bacterial infection, subarachnoid hemorrhage, stroke, and intracranial mass.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     HACE diagnosis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;High altitude cerebral edema (HACE) generally occurs in individuals with acute mountain sickness (AMS)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    high altitude pulmonary edema (HAPE) at elevations over 3000 to 3500 m [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/17\">",
"     17",
"    </a>",
"    ]. The hallmarks of HACE are encephalopathic symptoms and signs, including ataxic gait [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/26\">",
"     26",
"    </a>",
"    ], severe lassitude, and progressive decline of mental function and consciousness (irritability, confusion, impaired mentation, drowsiness, stupor, and finally coma).",
"   </p>",
"   <p>",
"    Signs of abnormal coordination, such as impaired performance of finger-to-nose and heel-to-shin testing, may be present. Focal neurologic findings, such as hemiparesis, slurred speech, or a discrete visual deficit, may rarely develop but are not typical and should raise concern for an alternative diagnosis, such as ischemic stroke, intracranial hemorrhage, or hypoglycemia.",
"   </p>",
"   <p>",
"    The onset of general neurological signs (ie, encephalopathy and ataxia) signifies the transition from AMS to HACE. This transition can occur unpredictably and may require as long as three days or as little as 12 hours. HACE develops faster in patients with HAPE, most likely as a result of severe hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients with HAPE manifest pulmonary findings, such as crackles. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28936?source=see_link\">",
"     \"High altitude pulmonary edema\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early symptoms of HACE may be missed or mistaken for exhaustion. Lethargy and irritability may manifest initially as diminished climbing performance, lack of participation in group activities, and the desire to be left alone. Even ataxia, the earliest physical sign of HACE, may be missed if the patient is lying in a tent, insisting that he is well and simply wants to be left alone.",
"   </p>",
"   <p>",
"    A working diagnosis of HACE can be made presumptively and treatment started in any patient with a history of recent ascent (especially above 3500 m) and signs of encephalopathy. After descent, the clinician can reconsider the differential diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/5,16\">",
"     5,16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'HACE treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the exception of brain MRI, ancillary testing is only useful for excluding other diagnoses.",
"   </p>",
"   <p>",
"    In HACE the white blood cell count may be elevated. Lumbar puncture may reveal an increased opening pressure, but evaluation of the cerebral spinal fluid reveals normal findings [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/16\">",
"     16",
"    </a>",
"    ]. Pulse oximetry shows hypoxemia, but according to several observational studies, it is not a reliable means for detecting AMS [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. Arterial blood gas often reveals exaggerated hypoxemia.",
"   </p>",
"   <p>",
"    A chest radiograph may reveal pulmonary edema. Computerized tomography (CT) of the brain may show cerebral edema and attenuation of signal more in the white matter than gray matter.",
"   </p>",
"   <p>",
"    MRI is more revealing, showing characteristic intense T2 signal in the white matter, especially the splenium of the corpus callosum, with no grey matter lesions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53871 \" href=\"UTD.htm?11/61/12244\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/17\">",
"     17",
"    </a>",
"    ]. There is no correlation between the severity of edema and subsequent clinical outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/3\">",
"     3",
"    </a>",
"    ]. Since MRI may remain abnormal for days to weeks, it can be useful to establish the diagnosis of HACE even after recovery. Hemosiderin deposits may be present on MRI years after HACE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     AMS treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of acute mountain sickness (AMS) is based upon symptom severity and, in mild cases, patient preference [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/31\">",
"     31",
"    </a>",
"    ]. Mild illness can be treated conservatively, while moderate to severe symptoms may require medication (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    ), supplemental oxygen, and occasionally descent. In the field, portable hyperbaric therapy may be available when supplemental oxygen is in short supply or unavailable. It is important that group members and the afflicted individual remain alert for any symptoms or signs of worsening disease, particularly at elevations where AMS may rapidly progress to high altitude cerebral edema (above 4000 m). The same general treatment approach is used for both children and adults.",
"   </p>",
"   <p>",
"    Individuals with symptoms of AMS must be discouraged from ascending to higher elevations until symptoms have subsided. This may be difficult in the face of implicit or explicit pressures from members of the patient's climbing or hiking group, who do not wish to disrupt their schedule, or the patient's own desire to keep climbing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Conservative treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AMS should avoid further ascent, limit physical activity, and seek further care if any symptoms worsen. They should avoid alcohol and other respiratory depressants because of the danger of exacerbating hypoxemia during sleep. Symptomatic treatment, such as basic analgesics for headache and antiemetics, is often helpful. With conservative treatment, most patients successfully acclimatize over 24 to 48 hours and symptoms resolve [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Symptomatic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic therapy for headache may include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    or other nonsteroidal antiinflammatory drugs.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"     Promethazine",
"    </a>",
"    and particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    may be useful for nausea and vomiting. We suggest avoiding sleeping medications; treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    is preferable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Descent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Descent is always effective treatment for AMS, but it is not mandatory or even necessary except in the setting of intractable symptoms or suspicion that illness is progressing. Descent to an altitude lower than that where symptoms started effectively reverses AMS. Although the person should descend as far as necessary for improvement, descending 500 to 1000 m (1600 to 3300 ft) is usually sufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals with AMS symptoms must NOT ascend to higher altitudes for sleeping. Doing so is a common reason for developing severe high altitude illness (HAI).",
"   </p>",
"   <p>",
"    AMS patients must be carefully monitored for any sign that illness is progressing and should descend immediately if symptoms worsen despite rest or treatment. Absolute indications for immediate descent include neurologic findings (ataxia or change in consciousness) and signs of pulmonary edema. Subtle changes such as irritability, lethargy, diminished performance, and dyspnea at rest should also alert team members that the patient may be progressing toward HACE or high altitude pulmonary edema (HAPE).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplemental oxygen effectively relieves the symptoms of AMS and can serve as an alternative to descent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/33\">",
"     33",
"    </a>",
"    ]. Low-flow oxygen (1 to 3",
"    <span class=\"nowrap\">",
"     L/min)",
"    </span>",
"    can be given by nasal cannula using a home oxygen concentrator, or stored oxygen if available. In the field, oxygen supplies are limited, and oxygen therapy provided at 0.5 to 1",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    may both relieve symptoms and help conserve supplies. Supplemental oxygen can also be used intermittently or as perceived necessary by the patient, based upon the severity of symptoms.",
"   </p>",
"   <p>",
"    Oxygen therapy is generally prescribed for 12 to 48 hours or during sleep only, if symptoms are not severe. Some patients will respond to short-term treatment of an hour or so and remain improved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Hyperbaric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Portable, lightweight (less than 5 kg), manually inflated hyperbaric chambers are common in remote mountain clinics and on expeditions, where supplemental oxygen supplies are limited. By increasing barometric pressure, hyperbaric bags are capable of simulating a descent of 2500 m or more, depending upon the altitude where they are used. They are effective without supplemental oxygen, or may be used with an oxygen cylinder in the chamber to augment effectiveness.",
"   </p>",
"   <p>",
"    One hour of treatment in a pressurized chamber relieves symptoms, although they return within 12 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/34\">",
"     34",
"    </a>",
"    ]. Nevertheless, hyperbaric bags can be an effective temporizing measure while awaiting descent or the benefits of medical therapy. With more severe illness, long-term (12 hours or more) treatment may be necessary to resolve AMS completely.",
"   </p>",
"   <p>",
"    Although effective, hyperbaric chambers are generally unnecessary for the treatment of AMS in the hospital setting and at lower elevations where supplemental oxygen alone is usually sufficient to alleviate symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6416840\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A summary of medications used to treat high altitude illness is provided (",
"    <a class=\"graphic graphic_table graphicRef76719 \" href=\"UTD.htm?40/16/41229\">",
"     table 4",
"    </a>",
"    ). The agents used to treat AMS are discussed in greater detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h4\">",
"     Acetazolamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    accelerates acclimatization to high altitude [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/35\">",
"     35",
"    </a>",
"    ]. Acetazolamide 250 mg taken orally twice daily may be prescribed for one to three days while the patient remains at the same altitude. Return to activity and further ascent are NOT advised until symptoms have resolved. The dosage of acetazolamide is debated, and ranges up to 750 mg daily, but generally 125 to 250 mg twice daily is sufficient to alleviate symptoms while minimizing side effects.",
"   </p>",
"   <p>",
"    Few studies have rigorously assessed the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    in the treatment (rather than prophylaxis) of AMS. Our approach is based primarily upon clinical experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h4\">",
"     Dexamethasone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    alleviates the symptoms of AMS, but does NOT improve acclimatization [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/6,36,37\">",
"     6,36,37",
"    </a>",
"    ]. Dexamethasone 4 mg taken orally or intramuscularly, up to every six hours, for one to two days can be prescribed alone, in lieu of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    , or in combination with acetazolamide. Most experts recommend against further ascent while taking dexamethasone alone because of the risk of symptoms recurring or worsening when the drug is stopped.",
"   </p>",
"   <p>",
"    Some providers prescribe both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (to relieve AMS symptoms) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    (to augment acclimatization). While side effects are generally minimal with one to two days of dexamethasone, hyperglycemia may occur. Use is generally limited to a duration of 48 to 72 hours, so tapered dosing is unnecessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     HACE treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike acute mountain sickness (AMS), high altitude cerebral edema (HACE) requires immediate intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/31\">",
"     31",
"    </a>",
"    ]. Descent is the definitive treatment.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    , supplemental oxygen, and hyperbaric therapy all play important roles in facilitating descent or temporizing illness until evacuation can be performed.",
"   </p>",
"   <p>",
"    HACE most often occurs in remote locations at altitudes over 3000 to 4000 m, from which immediate descent may not be feasible. Therefore, early recognition and treatment are critical. The most important action is to evacuate the patient to lower altitude before their condition renders them unable to care for themselves or assist with descent. If immediate descent is not possible, portable hyperbaric therapy and oxygen may be lifesaving [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/5,16,17\">",
"     5,16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Descent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate descent at the first suspicion of HACE, while the victim is still ambulatory, is crucial to a favorable outcome. Evacuation becomes far more onerous, and potentially impossible, once the patient is nonambulatory, comatose, or requires airway management. Descent should be made to the nearest hospital capable of providing intensive therapy. Based upon clinical experience, a descent of approximately 1000 m is usually lifesaving [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Dexamethasone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    is a critical rescue medication for all extended excursions above 3000 to 4000 m where medical care is not available. It should be administered immediately upon the first suspicion of HACE (usually ataxia or change in consciousness) at an initial dose of 8 to 10 mg orally, intramuscularly (IM), or intravenously (IV), followed by 4 mg every six hours until complete descent is achieved. Dexamethasone works well when provided early in the course of HACE, and may markedly improve the patient's condition and ability to assist with evacuation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    is NOT a substitute for immediate descent. Unlike",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    , dexamethasone does not facilitate acclimatization and may give a false sense of security when symptoms diminish [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/40\">",
"     40",
"    </a>",
"    ]. Symptoms can recur once the drug is stopped if descent has not been accomplished [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No clinical studies have rigorously assessed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    for the treatment (rather than prophylaxis) of HACE. The use of dexamethasone described here is based primarily upon broad clinical experience. Treatment with other glucocorticoids may also be effective, but this has not been studied clinically. A summary of medications used to treat high altitude illness is provided (",
"    <a class=\"graphic graphic_table graphicRef76719 \" href=\"UTD.htm?40/16/41229\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sufficient oxygen should be given to maintain the SpO2 above 90 percent (if oximetry is available) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/5,16,17\">",
"     5,16,17",
"    </a>",
"    ]. Flow of 2 to 4",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    by facemask or nasal cannula is generally adequate. However, high flow oxygen should be given if high altitude pulmonary edema (HAPE) coexists. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28936?source=see_link\">",
"     \"High altitude pulmonary edema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Hyperbaric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although formal studies are lacking, treatment in a portable, manually inflated hyperbaric chamber may be lifesaving when circumstances conspire to prevent immediate descent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/5,41,42\">",
"     5,41,42",
"    </a>",
"    ]. For HACE, hyperbaric treatment should be combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    and supplemental oxygen, if available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Comatose patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comatose patients may be treated in a portable hyperbaric chamber, but with appropriate precautions to protect the airway. Systemic hypotension will cause cerebral ischemia and must be avoided. Therefore, judicious IV hydration with isotonic crystalloid may be necessary. Comatose patients require bladder catheterization to help assess fluid status, in addition to usual care.",
"   </p>",
"   <p>",
"    The management of patients with HACE who require mechanical ventilation can be difficult. Attempting to reduce intracranial pressure (ICP) by intubation and hyperventilation may be reasonable, but these patients have a respiratory alkalosis and over-ventilation could cause cerebral ischemia. Oxygen alone markedly decreases cerebral blood flow and ICP at high altitude. Therefore, these patients should not be hyperventilated if they are well oxygenated. The fraction of inspired oxygen (FiO2) should be increased if oxygenation is inadequate, rather than alternative maneuvers that may increase airway pressures, thereby potentially raising ICP.",
"   </p>",
"   <p>",
"    Once transferred to a hospital where monitoring is possible, other measures to reduce ICP may be attempted, if it remains elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/16\">",
"     16",
"    </a>",
"    ]. Emergent consultation with neurology and neurosurgery should be obtained. Although ICP may normalize with oxygen and descent, prolonged unconsciousness may result from the metabolic consequences of hypoxia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In less severe cases, recovery is often rapid upon descent. Others may remain comatose for days and not fully recover for weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/3\">",
"     3",
"    </a>",
"    ]. In such prolonged cases, other causes for coma must be thoroughly assessed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=see_link\">",
"     \"Stupor and coma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HACE may reach an irreversible stage before descent, in which case the patient will die regardless of evacuation, medication, or other treatment. In survivors, HACE can cause long-term sequelae and even permanent impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/3,43\">",
"     3,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC PREVENTION OF AMS/HACE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, clinicians should reserve prophylactic medications for high-to-moderate risk situations, particularly individuals with a history of altitude intolerance who must ascend at a similar rate and those making a rapid ascent to high altitude. Even in individuals with a history of HAI, gradual ascent should be emphasized over pharmacologic prophylaxis. Often, ascending at a slower rate than the previous offending ascent allows individuals to avoid illness. Nonpharmacologic measures to prevent HAI illness are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=see_link\">",
"     \"High altitude illness: Physiology, risk factors, and general prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For those at high-to-moderate risk, prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    may be beneficial. Acetazolamide is the drug of choice; dexamethasone is used when acetazolamide is not tolerated and in special circumstances. A summary of medications used for treatment and prophylaxis against high altitude illness is provided (",
"    <a class=\"graphic graphic_table graphicRef76719 \" href=\"UTD.htm?40/16/41229\">",
"     table 4",
"    </a>",
"    ). The agents used for prophylaxis against AMS and HACE are discussed in greater detail below.",
"   </p>",
"   <p>",
"    Prophylactic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    should be given to individuals with a history of HAI who ascend to altitudes above 2500 m. It is also reasonable to give acetazolamide to individuals without such a history who travel directly from low altitude (near sea level) to altitudes above 2800 m, at which the incidence of AMS rises substantially. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'AMS epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    An example of a special circumstance in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    is given would be a rescue team required to ascend rapidly above 3500 m on short notice. For such a scenario, we suggest prophylaxis with dexamethasone 2 to 4 mg four times daily, beginning before the ascent if possible and continued until descent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/5\">",
"     5",
"    </a>",
"    ]. In this circumstance where acclimatization is not possible, dexamethasone is a better choice for prophylaxis because it is relatively rapid acting, highly effective, and does not depend upon acclimatization for effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Acetazolamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     Acetazolamide",
"    </a>",
"    is the drug of choice for the prevention of AMS when rapid ascent cannot be avoided, particularly in individuals with a history of AMS. Multiple randomized trials have found that acetazolamide reduces symptoms of AMS by approximately 75 percent when used as a single-agent for this purpose [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/25,44-48\">",
"     25,44-48",
"    </a>",
"    ]. Systematic reviews of these studies confirm the drug&rsquo;s effectiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ideal dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    for AMS prophylaxis is debated. A clinically effective preventive dose that also minimizes side effects is 125 mg every 12 hours (250 mg daily), although most clinical trials have been performed with higher doses [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/17,35,50-52\">",
"     17,35,50-52",
"    </a>",
"    ]. Some experts suggest that the dose at which renal carbonic anhydrase is blocked (5",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    is ideal, but no clinical trial has demonstrated superior results using a weight-based regimen in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/17\">",
"     17",
"    </a>",
"    ]. For prevention, higher doses are unlikely to provide added benefit, but do increase the incidence of side effects.",
"   </p>",
"   <p>",
"    The most notable side effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    is peripheral paresthesia. Others include polyuria, flattened taste of carbonated beverages, and less commonly, nausea, drowsiness, impotence, and myopia. Acetazolamide can induce hypersensitivity, allergic reactions, and, rarely, anaphylaxis.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     Acetazolamide",
"    </a>",
"    is a sulfonamide drug, although it belongs to the group of sulfonamide NON-antimicrobials, which are believed to have minimal cross-reactivity with sulfonamide antimicrobials, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    . Despite this, most product inserts list allergy to any sulfonamide as a possible contraindication to the use of acetazolamide. Therefore, patients with a history of significant allergic reactions to other sulfonamide drugs should be evaluated before travel to determine if acetazolamide is tolerated. This evaluation is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23594?source=see_link&amp;anchor=H20#H20\">",
"     \"Sulfonamide allergy in non HIV-infected patients\", section on 'Cross-reactivity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Duration of treatment depends upon the ascent profile. Individuals ascending to a fixed sleeping altitude (eg, recreational skiers) may start",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    the day before ascent and continue treatment for 48 hours. If further ascent is planned, acetazolamide can be continued until maximum elevation is attained. Acetazolamide can also be taken episodically to speed acclimatization at any point while gaining altitude or to treat mild AMS. Symptoms do not recur when the drug is discontinued. Although the danger of AMS passes after a few days of acclimatization, acetazolamide may still be useful for sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     Acetazolamide",
"    </a>",
"    is a carbonic anhydrase (CA) inhibitor affecting multiple organ systems, including red blood cells, brain, lungs, and kidneys. It works by a number of mechanisms to accelerate acclimatization and ameliorate hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Inhibition of renal CA slows the hydration of carbon dioxide, reduces reabsorption of bicarbonate and sodium, and causes a bicarbonate diuresis with resultant metabolic acidosis starting within one hour of ingestion.",
"   </p>",
"   <p>",
"    By disinhibiting the central chemoreceptors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    stimulates ventilation, which rapidly improves oxygenation. Importantly, acetazolamide maintains oxygenation during sleep and prevents periods of extreme hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Acetazolamide's diuretic action helps to counteract fluid retention associated with HAI. It also diminishes nocturnal antidiuretic hormone (ADH) secretion and cerebrospinal fluid production and volume, and possibly lowers intracranial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/17,57\">",
"     17,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Dexamethasone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    is effective for prevention of",
"    <span class=\"nowrap\">",
"     AMS/HACE,",
"    </span>",
"    but does not aid acclimatization. There is a risk of a sudden onset or worsening of symptoms if the traveler discontinues the drug while ascending. For this reason, and because of potential side effects, experts recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    for AMS prevention and reserve dexamethasone for treatment. Dexamethasone should not be taken for more than seven days in order to avoid hyperglycemia, hypercalciuria, protein catabolism, immune suppression, and psychiatric effects.",
"   </p>",
"   <p>",
"    Nevertheless,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    can be an important adjunctive therapy for individuals ascending rapidly to altitudes higher than 3000 m, or for use in patients who are allergic to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    . A dose of 2 mg every 6 hours or 4 mg every 12 hours is sufficient for sedentary subjects. For exercising subjects at or above 4000 m, this dose is insufficient, and 4 mg every six hours is necessary to prevent AMS [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effectiveness of prophylactic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    has been demonstrated in several small randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/36,59-62\">",
"     36,59-62",
"    </a>",
"    ]. In one such trial, 13 climbers acclimatized for two days at 3698 m and then ascended to 5334 m over a two day period [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/60\">",
"     60",
"    </a>",
"    ]. No evidence of AMS was found in those given prophylactic treatment with both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    and dexamethasone, while evidence of AMS was found in those treated with acetazolamide and placebo.",
"   </p>",
"   <p>",
"    Euphoria and mental disorientation are complications feared by some, but several studies have failed to demonstrate such symptoms. Other studies have found improvements in reaction times and mood among those using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    prophylaxis, with no ill effects identified by cognitive and psychomotor tests [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prophylaxis with other glucocorticoids may also be effective, but this has not been well studied clinically [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory medications (NSAIDs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    have been shown to prevent headache on ascent to high altitude [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. Since headache is the cardinal symptom of AMS, and required for the research definition of the disease, it follows that these agents &ldquo;prevent&rdquo; AMS. For those going to moderate altitude (ie, below 3500 m), aspirin or ibuprofen may be useful for preventing the headache associated with AMS. However, it remains unclear whether these medications would be useful as prophylaxis, or treatment, in high-risk situations (ie, rapid ascent to very high or extreme altitude) or for more severe disease. The limitations of trials involving NSAIDs make such determinations difficult.",
"   </p>",
"   <p>",
"    As an example, a randomized trial reported that fewer climbers given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    for prophylaxis developed AMS (19 of 44, 43 percent) compared to those given placebo (29 of 42, 69 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/69\">",
"     69",
"    </a>",
"    ]. However, the study used less stringent criteria to define AMS (Lake Louise Score &ge;3, rather than &ge;5), involved small numbers, and did not compare ibuprofen to established prophylaxis treatments for either AMS or headache. In a similar trial with 232 participants, ibuprofen was not compared to established treatments and the incidence of severe AMS (Lake Louise Score &ge;5) did not differ significantly regardless of whether analysis was performed using an intent-to-treat (13 in placebo group vs 11 in treatment group) or treatment-completed approach (7 in placebo group vs 9 in treatment group) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Ginkgo biloba",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ginkgo biloba is a complex herbal extract preparation, with many active ingredients. While some small studies suggest that ginkgo biloba is effective at reducing the symptoms of AMS in adults, larger trials have failed to demonstrate benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?1/6/1130/abstract/49,71\">",
"     49,71",
"    </a>",
"    ]. The use of ginkgo biloba is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/28/11720?source=see_link\">",
"     \"Clinical use of ginkgo biloba\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/18/23842?source=see_link\">",
"       \"Patient information: Altitude sickness (including mountain sickness) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?4/19/4403?source=see_link\">",
"       \"Patient information: High altitude illness (including mountain sickness) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute mountain sickness (AMS) and high altitude cerebral edema (HACE) are considered to represent two points along a single spectrum of disease, with the same underlying pathophysiology. Increased cerebral vascular permeability is a central feature that occurs through a number of mechanisms. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AMS is the most common high altitude illness (HAI). As with all HAI, incidence depends upon individual susceptibility, the elevation reached, and the rate of ascent. The epidemiology of AMS and HACE are discussed further in the text; general risk factors for HAI are discussed separately. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=see_link\">",
"       \"High altitude illness: Physiology, risk factors, and general prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      AMS is diagnosed clinically in a person who lives at low altitude but has recently ascended to high altitude (generally over 2000 m). Symptoms resemble those of an alcohol hangover: primarily headache often associated with fatigue, lightheadedness, anorexia, nausea and vomiting, disturbed sleep, and mild shortness of breath with exertion. Onset of AMS is usually delayed for 6 to 12 hours following arrival at high altitude, but can occur as rapidly as one to two hours or as late as 24 hours. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'AMS diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HACE generally occurs in individuals with AMS",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      high altitude pulmonary edema (HAPE) at elevations over 3000 to 3500 m. The hallmarks of HACE are encephalopathic symptoms and signs, including ataxic gait, severe lassitude, and progressive decline of mental function and consciousness (irritability, confusion, impaired mentation, drowsiness, stupor, and finally coma). The onset of encephalopathy and ataxia signifies the transition from AMS to HACE and occurs unpredictably, requiring as long as three days or as little as 12 hours. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'HACE diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of AMS is based upon symptom severity. Mild illness can be managed conservatively (avoid ascent, limit activity) with symptomatic treatment (eg, analgesic, antiemetic); moderate to severe symptoms may require medication (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      ), supplemental oxygen, and occasionally descent. In the field, portable hyperbaric therapy may helpful. It is important that group members and the afflicted individual remain alert for any symptoms or signs of worsening disease, particularly at elevations where AMS may rapidly progress to HACE (above 4000 m). The same general treatment approach is used for both children and adults. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'AMS treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early recognition and treatment of HACE are critical. Descent is the definitive treatment and should begin immediately at the first suspicion of HACE.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      and supplemental oxygen play important roles in facilitating descent or temporizing illness until evacuation can be performed. The most important action is to evacuate the patient to lower altitude before their condition renders them unable to assist with descent. If immediate descent is not possible, portable hyperbaric therapy and oxygen may be lifesaving. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'HACE treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We administer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      immediately upon the first suspicion of HACE. The initial dose is 8 to 10 mg given orally, intramuscularly (IM), or intravenously (IV), followed by 4 mg every six hours until complete descent is achieved. Dexamethasone is NOT a substitute for immediate descent. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'HACE treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Dexamethasone'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Prophylaxis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinicians should reserve prophylactic medications for high-to-moderate risk situations, particularly individuals with a history of altitude intolerance. Even in individuals with a previous history of HAI, gradual ascent should be emphasized over pharmacologic prophylaxis. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prophylactic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      should be given to individuals with a history of HAI who ascend to altitudes above 2500 m. It is also reasonable to give acetazolamide to individuals without such a history who travel directly from low altitude (near sea level) to altitudes above 2800 m. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Acetazolamide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      General nonpharmacologic measures to prevent HAI illness are discussed separately. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Pharmacologic prevention of AMS/HACE'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=see_link\">",
"       \"High altitude illness: Physiology, risk factors, and general prevention\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94659894\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/1\">",
"      Wilson MH, Newman S, Imray CH. The cerebral effects of ascent to high altitudes. Lancet Neurol 2009; 8:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/2\">",
"      Bailey DM, B&auml;rtsch P, Knauth M, Baumgartner RW. Emerging concepts in acute mountain sickness and high-altitude cerebral edema: from the molecular to the morphological. Cell Mol Life Sci 2009; 66:3583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/3\">",
"      Hackett PH, Yarnell PR, Hill R, et al. High-altitude cerebral edema evaluated with magnetic resonance imaging: clinical correlation and pathophysiology. JAMA 1998; 280:1920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/4\">",
"      Severinghaus JW, Chiodi H, Eger EI 2nd, et al. Cerebral blood flow in man at high altitude. Role of cerebrospinal fluid pH in normalization of flow in chronic hypocapnia. Circ Res 1966; 19:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/5\">",
"      Schoene RB. Illnesses at high altitude. Chest 2008; 134:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/6\">",
"      West JB, American College of Physicians, American Physiological Society. The physiologic basis of high-altitude diseases. Ann Intern Med 2004; 141:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/7\">",
"      Kallenberg K, Dehnert C, D&ouml;rfler A, et al. Microhemorrhages in nonfatal high-altitude cerebral edema. J Cereb Blood Flow Metab 2008; 28:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/8\">",
"      Clarke C. Acute mountain sickness: medical problems associated with acute and subacute exposure to hypobaric hypoxia. Postgrad Med J 2006; 82:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/9\">",
"      Dickinson J, Heath D, Gosney J, Williams D. Altitude-related deaths in seven trekkers in the Himalayas. Thorax 1983; 38:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/10\">",
"      Song SY, Asaji T, Tanizaki Y, et al. Cerebral thrombosis at altitude: its pathogenesis and the problems of prevention and treatment. Aviat Space Environ Med 1986; 57:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/11\">",
"      Ross RT. The random nature of cerebral mountain sickness. Lancet 1985; 1:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/12\">",
"      Sanchez del Rio M, Moskowitz MA. High altitude headache. Lessons from headaches at sea level. Adv Exp Med Biol 1999; 474:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/13\">",
"      Murdoch DR. Altitude Illness Among Tourists Flying to 3740 Meters Elevation in the Nepal Himalayas. J Travel Med 1995; 2:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/14\">",
"      Larson EB, Roach RC, Schoene RB, Hornbein TF. Acute mountain sickness and acetazolamide. Clinical efficacy and effect on ventilation. JAMA 1982; 248:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/15\">",
"      Hackett, PH. The Denali Medical Research Project, 1982-1985. Am Alpine J 1986; 28:129.",
"     </a>",
"    </li>",
"    <li>",
"     West JB, Schoene RB, Milledge JS. High Altitude Medicine and Physiology, Hodder Arnold, London 2007.",
"    </li>",
"    <li>",
"     Hackett PH, Roach RC. High altitude medicine. In: Wilderness Medicine, 5th, Auerbach PS (Ed), Mosby, Philadelphia 2007. p.2.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/18\">",
"      Schneider M, Bernasch D, Weymann J, et al. Acute mountain sickness: influence of susceptibility, preexposure, and ascent rate. Med Sci Sports Exerc 2002; 34:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/19\">",
"      Silber E, Sonnenberg P, Collier DJ, et al. Clinical features of headache at altitude: a prospective study. Neurology 2003; 60:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/20\">",
"      Vann RD, Pollock NW, Pieper CF, et al. Statistical models of acute mountain sickness. High Alt Med Biol 2005; 6:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/21\">",
"      Theis MK, Honigman B, Yip R, et al. Acute mountain sickness in children at 2835 meters. Am J Dis Child 1993; 147:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/22\">",
"      Yaron M, Waldman N, Niermeyer S, et al. The diagnosis of acute mountain sickness in preverbal children. Arch Pediatr Adolesc Med 1998; 152:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/23\">",
"      Wu TY, Ding SQ, Liu JL, et al. Who should not go high: chronic disease and work at altitude during construction of the Qinghai-Tibet railroad. High Alt Med Biol 2007; 8:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/24\">",
"      Dickinson JG. Severe acute mountain sickness. Postgrad Med J 1979; 55:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/25\">",
"      Hackett PH, Rennie D, Levine HD. The incidence, importance, and prophylaxis of acute mountain sickness. Lancet 1976; 2:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/26\">",
"      Bird BA, Wright AD, Wilson MH, et al. High altitude ataxia--its assessment and relevance. Wilderness Environ Med 2011; 22:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/27\">",
"      Chen HC, Lin WL, Wu JY, et al. Change in oxygen saturation does not predict acute mountain sickness on Jade Mountain. Wilderness Environ Med 2012; 23:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/28\">",
"      O'Connor T, Dubowitz G, Bickler PE. Pulse oximetry in the diagnosis of acute mountain sickness. High Alt Med Biol 2004; 5:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/29\">",
"      Wagner DR, Knott JR, Fry JP. Oximetry fails to predict acute mountain sickness or summit success during a rapid ascent to 5640 meters. Wilderness Environ Med 2012; 23:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/30\">",
"      Karinen HM, Peltonen JE, K&auml;h&ouml;nen M, Tikkanen HO. Prediction of acute mountain sickness by monitoring arterial oxygen saturation during ascent. High Alt Med Biol 2010; 11:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/31\">",
"      Luks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness. Wilderness Environ Med 2010; 21:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/32\">",
"      Hackett PH, Roach RC. High-altitude illness. N Engl J Med 2001; 345:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/33\">",
"      B&auml;rtsch P, Baumgartner RW, Waber U, et al. Comparison of carbon-dioxide-enriched, oxygen-enriched, and normal air in treatment of acute mountain sickness. Lancet 1990; 336:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/34\">",
"      B&auml;rtsch P, Merki B, Hofstetter D, et al. Treatment of acute mountain sickness by simulated descent: a randomised controlled trial. BMJ 1993; 306:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/35\">",
"      Grissom CK, Roach RC, Sarnquist FH, Hackett PH. Acetazolamide in the treatment of acute mountain sickness: clinical efficacy and effect on gas exchange. Ann Intern Med 1992; 116:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/36\">",
"      Hackett PH, Roach RC, Wood RA, et al. Dexamethasone for prevention and treatment of acute mountain sickness. Aviat Space Environ Med 1988; 59:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/37\">",
"      Keller HR, Maggiorini M, B&auml;rtsch P, Oelz O. Simulated descent v dexamethasone in treatment of acute mountain sickness: a randomised trial. BMJ 1995; 310:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/38\">",
"      Hackett PH, Roach RC. High altitude cerebral edema. High Alt Med Biol 2004; 5:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/39\">",
"      Ferrazzini G, Maggiorini M, Kriemler S, et al. Successful treatment of acute mountain sickness with dexamethasone. Br Med J (Clin Res Ed) 1987; 294:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/40\">",
"      Levine BD, Yoshimura K, Kobayashi T, et al. Dexamethasone in the treatment of acute mountain sickness. N Engl J Med 1989; 321:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/41\">",
"      Freeman K, Shalit M, Stroh G. Use of the Gamow Bag by EMT-basic park rangers for treatment of high-altitude pulmonary edema and high-altitude cerebral edema. Wilderness Environ Med 2004; 15:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/42\">",
"      Zafren K. Gamow bag for high-altitude cerebral oedema. Lancet 1998; 352:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/43\">",
"      Houston CS, Dickinson J. Cerebral form of high-altitude illness. Lancet 1975; 2:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/44\">",
"      Forwand SA, Landowne M, Follansbee JN, Hansen JE. Effect of acetazolamide on acute mountain sickness. N Engl J Med 1968; 279:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/45\">",
"      Basnyat B, Gertsch JH, Holck PS, et al. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Alt Med Biol 2006; 7:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/46\">",
"      van Patot MC, Leadbetter G 3rd, Keyes LE, et al. Prophylactic low-dose acetazolamide reduces the incidence and severity of acute mountain sickness. High Alt Med Biol 2008; 9:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/47\">",
"      Pollard AJ, Niermeyer S, Barry P, et al. Children at high altitude: an international consensus statement by an ad hoc committee of the International Society for Mountain Medicine, March 12, 2001. High Alt Med Biol 2001; 2:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/48\">",
"      Ellsworth AJ, Larson EB, Strickland D. A randomized trial of dexamethasone and acetazolamide for acute mountain sickness prophylaxis. Am J Med 1987; 83:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/49\">",
"      Seupaul RA, Welch JL, Malka ST, Emmett TW. Pharmacologic prophylaxis for acute mountain sickness: a systematic shortcut review. Ann Emerg Med 2012; 59:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/50\">",
"      Low EV, Avery AJ, Gupta V, et al. Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic review and meta-analysis. BMJ 2012; 345:e6779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/51\">",
"      Carlsten C, Swenson ER, Ruoss S. A dose-response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m). High Alt Med Biol 2004; 5:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/52\">",
"      Basnyat B, Gertsch JH, Johnson EW, et al. Efficacy of low-dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial. High Alt Med Biol 2003; 4:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/53\">",
"      Swenson ER. Carbonic anhydrase inhibitors and hypoxic pulmonary vasoconstriction. Respir Physiol Neurobiol 2006; 151:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/54\">",
"      Teppema LJ, Balanos GM, Steinback CD, et al. Effects of acetazolamide on ventilatory, cerebrovascular, and pulmonary vascular responses to hypoxia. Am J Respir Crit Care Med 2007; 175:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/55\">",
"      Hackett PH, Roach RC, Hartig GS, et al. The effect of vasodilators on pulmonary hemodynamics in high altitude pulmonary edema: a comparison. Int J Sports Med 1992; 13 Suppl 1:S68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/56\">",
"      Sutton JR, Reeves JT, Wagner PD, et al. Operation Everest II: oxygen transport during exercise at extreme simulated altitude. J Appl Physiol 1988; 64:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/57\">",
"      Senay LC Jr, Tolbert DL. Effect of arginine vasopressin, acetazolamide, and angiotensin II on CSF pressure at simulated altitude. Aviat Space Environ Med 1984; 55:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/58\">",
"      Rock PB, Johnson TS, Larsen RF, et al. Dexamethasone as prophylaxis for acute mountain sickness. Effect of dose level. Chest 1989; 95:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/59\">",
"      Ellsworth AJ, Meyer EF, Larson EB. Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier. West J Med 1991; 154:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/60\">",
"      Bernhard WN, Schalick LM, Delaney PA, et al. Acetazolamide plus low-dose dexamethasone is better than acetazolamide alone to ameliorate symptoms of acute mountain sickness. Aviat Space Environ Med 1998; 69:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/61\">",
"      Hussain MM, Aslam M. Hypoxia and pulmonary acclimatisation at 4578 m altitude: the role of acetazolamide and dexamethasone. J Pak Med Assoc 2003; 53:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/62\">",
"      Rock PB, Johnson TS, Cymerman A, et al. Effect of dexamethasone on symptoms of acute mountain sickness at Pikes Peak, Colorado (4,300 m). Aviat Space Environ Med 1987; 58:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/63\">",
"      Lafleur J, Giron M, Demarco M, et al. Cognitive effects of dexamethasone at high altitude. Wilderness Environ Med 2003; 14:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/64\">",
"      Jobe JB, Shukitt-Hale B, Banderet LE, Rock PB. Effects of dexamethasone and high terrestrial altitude on cognitive performance and affect. Aviat Space Environ Med 1991; 62:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/65\">",
"      Basu M, Sawhney RC, Kumar S, et al. Glucocorticoids as prophylaxis against acute mountain sickness. Clin Endocrinol (Oxf) 2002; 57:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/66\">",
"      Burtscher M, Likar R, Nachbauer W, Philadelphy M. Aspirin for prophylaxis against headache at high altitudes: randomised, double blind, placebo controlled trial. BMJ 1998; 316:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/67\">",
"      Burtscher M, Likar R, Nachbauer W, et al. Effects of aspirin during exercise on the incidence of high-altitude headache: a randomized, double-blind, placebo-controlled trial. Headache 2001; 41:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/68\">",
"      Broome JR, Stoneham MD, Beeley JM, et al. High altitude headache: treatment with ibuprofen. Aviat Space Environ Med 1994; 65:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/69\">",
"      Lipman GS, Kanaan NC, Holck PS, et al. Ibuprofen prevents altitude illness: a randomized controlled trial for prevention of altitude illness with nonsteroidal anti-inflammatories. Ann Emerg Med 2012; 59:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/70\">",
"      Gertsch JH, Corbett B, Holck PS, et al. Altitude Sickness in Climbers and Efficacy of NSAIDs Trial (ASCENT): randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness. Wilderness Environ Med 2012; 23:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/6/1130/abstract/71\">",
"      Gertsch JH, Basnyat B, Johnson EW, et al. Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ 2004; 328:797.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 182 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-110.170.48.130-053DC9DE2B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_6_1130=[""].join("\n");
var outline_f1_6_1130=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      AMS epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HACE epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PRESENTATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      AMS diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HACE diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      AMS treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - General approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Conservative treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Symptomatic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Descent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Oxygen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Hyperbaric therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6416840\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Acetazolamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Dexamethasone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      HACE treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - General approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Descent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Dexamethasone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Oxygen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Hyperbaric therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Comatose patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PHARMACOLOGIC PREVENTION OF AMS/HACE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Acetazolamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Dexamethasone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Nonsteroidal antiinflammatory medications (NSAIDs)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Ginkgo biloba",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94659894\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/182\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/182|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/61/12244\" title=\"diagnostic image 1\">",
"      HACE MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/182|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/24/8588\" title=\"table 1\">",
"      Physiologic effects of high altitude",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/4/71\" title=\"table 2\">",
"      High altitude sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/23/42364\" title=\"table 3\">",
"      Lake Louise AMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/16/41229\" title=\"table 4\">",
"      Pharmacologic treatment of high altitude illness",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/28/11720?source=related_link\">",
"      Clinical use of ginkgo biloba",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27769?source=related_link\">",
"      High altitude disease: Unique pediatric considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=related_link\">",
"      High altitude illness: Physiology, risk factors, and general prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28936?source=related_link\">",
"      High altitude pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/18/23842?source=related_link\">",
"      Patient information: Altitude sickness (including mountain sickness) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/19/4403?source=related_link\">",
"      Patient information: High altitude illness (including mountain sickness) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=related_link\">",
"      Stupor and coma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23594?source=related_link\">",
"      Sulfonamide allergy in non HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_6_1131="Causes Meniere disease";
var content_f1_6_1131=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66900&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66900&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions that may cause symptoms of Meniere disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Hyper/hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central nervous system disease (eg, cerebral vascular",
"insufficiency, aneurysm, multiple sclerosis, concussive syndrome,",
"tumor, pseudotumor cerebri)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent vestibular neuronitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurosyphilis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_6_1131=[""].join("\n");
var outline_f1_6_1131=null;
var title_f1_6_1132="Causes of venous thrombosis";
var content_f1_6_1132=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F59759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F59759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors (causes) for the development of venous thrombosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inherited thrombophilia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Factor V Leiden mutation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prothrombin gene mutation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protein S deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protein C deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antithrombin (AT) deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Rare disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dysfibrinogenemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Acquired disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presence of a central venous catheter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surgery, especially orthopedic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral contraceptives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hormone replacement therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tamoxifen, Thalidomide, Lenalidomide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immobilization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congestive failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antiphospholipid antibody syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Myeloproliferative disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Polycythemia vera",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Essential thrombocythemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paroxysmal nocturnal hemoglobinuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory bowel disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nephrotic syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_6_1132=[""].join("\n");
var outline_f1_6_1132=null;
var title_f1_6_1133="Proof for mitochondrial dysfunction";
var content_f1_6_1133=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Scientific proof for mitochondrial dysfunction as pathway for side effects of NRTI at tissue level",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        NRTIs involved",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Mitochondrial pathway demonstrated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Mitochondrial structure",
"       </td>",
"       <td class=\"subtitle2\">",
"        [mtDNA]",
"       </td>",
"       <td class=\"subtitle2\">",
"        mtDNA proteins",
"       </td>",
"       <td class=\"subtitle2\">",
"        Mitochondrial function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skeletal myopathy",
"       </td>",
"       <td>",
"        AZT",
"       </td>",
"       <td>",
"        Abnormal, RRF",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiomyopathy",
"       </td>",
"       <td>",
"        AZT, d4T",
"       </td>",
"       <td>",
"        Abnormal",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuropathy",
"       </td>",
"       <td>",
"        ddC, d4T, ddI",
"       </td>",
"       <td>",
"        Abnormal",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Macrocytosis",
"       </td>",
"       <td>",
"        AZT, d4T",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatitis",
"       </td>",
"       <td>",
"        ddI",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatic steatosis",
"       </td>",
"       <td>",
"        AZT, ddI, d4T",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lactic acidosis",
"       </td>",
"       <td>",
"        ddI, d4T, AZT",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        (PBMCs)",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lipodystrophy",
"       </td>",
"       <td>",
"        d4T&gt;AZT",
"       </td>",
"       <td>",
"        Abnormal",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proximal tubular dysfunction",
"       </td>",
"       <td>",
"        TDF",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osteopenia",
"       </td>",
"       <td>",
"        TDF",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Mitochondrial toxicity is the major cause of NRTI-induced myopathy, neuropathy, lipoatrophy, and lactic acidosis. Whether mitochondrial toxicity is involved in pancreatitis, myelosuppression, cardiomyopathy, proximal tubular dysfunction or osteopenia is not as clear.",
"    <div class=\"footnotes\">",
"     ND: not done; ?: studied but inconclusive; -: deleted/diminished; RRF: ragged red fibers; PBMC: peripheral blood mononuclear cells; NRTI: nucleoside reverse transcriptase inhibitor; d4T: stavudine; ddI: didanosine; ddC: zalcitabine (no longer available); AZT: zidovudine; TDF: tenofovir.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kees Brinkman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_6_1133=[""].join("\n");
var outline_f1_6_1133=null;
var title_f1_6_1134="Treatment of the severely malnourished child";
var content_f1_6_1134=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 583px\">",
"   <div class=\"ttl\">",
"    Approximate time-scale for the 10 steps for treatment of severe malnutrition",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 563px; height: 374px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Improving child nutrition: Treating severe malnutrition. Child Health Dialogue 2000; 19. Copyright &copy; 2000 Healthlink.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_6_1134=[""].join("\n");
var outline_f1_6_1134=null;
var title_f1_6_1135="STS survival by primary site";
var content_f1_6_1135=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F71632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F71632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Survival in primary soft tissue sarcoma according to primary site",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 397px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Survival curves for different primary sites are based upon data from 3677 patients with soft tissue sarcoma evaluated at Memorial Sloan-Kettering Cancer Center, 1982-2001.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Borden EC, Baker LH, Bell RS, et al. Soft tissue sarcomas of adults: State of the translational science. Clin Cancer Res 2003; 9:1941.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_6_1135=[""].join("\n");
var outline_f1_6_1135=null;
